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 ABSTRACT  
 
Lynch Syndrome (LS) is associated with an increased risk of colorectal (CRC) and 
other cancers. High risk individuals can be detected by testing all CRC tumors for 
findings such as microsatellite instability suggestive of LS, known as ‘universal 
tumor screening’. Patient interest in screening and preferences for consent remain 
largely unknown. To explore the perspectives of CRC patients about universal 
tumor screening, a postal survey was administered to patients in NL diagnosed 
with CRC from 2014-2016 (n=698). Response rate was 47.6%. A large majority of 
patients (81.4 %) were willing to have their tumors tested if such a program were 
available in NL. Nearly all were willing to discuss their test result with family 
members and healthcare professionals, and the majority (62.6%) preferred 
informed consent be obtained prior to screening. While patients were supportive of 
tumor screening to identify LS, they expected some form of consent to be obtained, 
contrary to current practice across Canada. Findings can help guide the 
implementation of a universal tumor screening program in NL. 
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CHAPTER 1 
 
 
 
INTRODUCTION  
 
  This chapter begins with an overview of the epidemiology of colorectal cancer 
(CRC) and hereditary colorectal cancer syndromes. The history of Lynch 
syndrome (LS), its clinicopathological features and various screening criteria, 
including molecular screening methods, are then described. In the subsequent 
sections, universal tumor screening for LS, and a literature review of various 
aspects of universal screening including its implications, barriers, and stakeholder 
perspectives are described. The final section of the chapter describes the objectives 
of the study.  
 
1.1 Epidemiology  
  Colorectal carcinoma (CRC) is the third most common malignancy in the world 
(Ferlay et al., 2015). In 2012, an estimated 1.4 million new CRC cases were 
diagnosed worldwide. It is the fourth most common cause of cancer-related death 
in the world. CRC, together with lung, prostate and breast cancer, accounts for 
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about half of all the cancer burden and is more common in areas with a high 
Human Development index (Bray, Jemal, Grey, Ferlay, & Forman, 2012).  
       In Canada, CRC is the second most common cancer, accounting for about 13% 
of all cancers (Canadian Cancer Society’s Advisory Committee on Cancer 
Statistics, 2017). Roughly 29,000 new cases were projected for the year 2017. 
Although the mortality rates of CRC have decreased in Canada, it is still the 
second leading cause of cancer death among males and third most common cause 
of cancer death among females and accounts for about 12% of all cancer deaths 
(Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2017). 
Newfoundland and Labrador (NL), has the highest incidence of CRC in the 
country. Canadian Cancer Statistics estimates roughly 620 new cases of CRC 
diagnosed in 2017 in NL (Canadian Cancer Society’s Advisory Committee on 
Cancer Statistics, 2017). It was estimated that the average lifetime cost of 
managing CRC patients in Canada ranged from $20,319 per case in stage I colon 
cancer to $39,182 per case for stage III rectal carcinoma. The lifetime treatment 
cost in Canada for all patients was over $333 million in the year 2000 (Maroun et 
al., 2003).  
  The vast majority of CRCs are sporadic in nature, caused due to environmental 
and lifestyle factors. However, kindred and twin studies revealed that 20-30% of 
colorectal cancers have a potentially identifiable genetic or familial origin 
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(Lichtenstein et al., 2000; Wells & Wise, 2017). These conditions are collectively 
called Hereditary Cancer Syndromes. Lynch Syndrome is the most common 
familial cancer, accounting for 3-5% of all CRC cases. This project will focus on 
tumor testing in the context of Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC), also known as Lynch syndrome (LS).  
   
1.2. Hereditary cancer syndromes  
  Classically, the hereditary cancer syndromes are classified based on the presence 
and type of intestinal polyps. They vary in their penetrance (i.e., lifetime risk of 
developing CRC if one carries a mutation), histological features, risk of 
extracolonic malignancies and other extra intestinal features (Jasperson, Tuohy, 
Neklason, & Burt, 2010).  Lynch Syndrome is a non-polyposis colon cancer 
syndrome. Other types include polyposis colon cancer syndrome and 
hamartomatous colon cancer syndromes. The important subtypes are briefly 
described below.  
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1.2.1 Polyposis Colon Cancer Syndromes (PCCS) 
   These syndromes are characterised by the development of adenomatous polyps 
along the gastrointestinal tract in varying numbers and site. Familial Adenomatous 
Polyposis (FAP), the second most common type of hereditary CRC, is an 
autosomal dominant genetic condition characterised by the development of 
hundreds of thousands of colonic polyps with a high rate of malignant 
transformation, normally in the second or third decade of life. The genetic basis 
lies in the mutation to the Adenomatous Polyposis Coli (APC) gene and the 
recommended management includes prophylactic total colectomy (Strate & 
Syngal, 2005). The variants of this condition include: Gardner syndrome, which 
features desmoid tumors, dental abnormalities, osteomas and soft tissue tumors; 
Turcot syndrome, characterised by additional central nervous system tumors such 
as astrocytoma; and Attenuated Adenomatous Polyposis Coli (AAPC) which is 
similar to FAP, but manifests as fewer (<100) intestinal polyps with later onset and 
lower risk of CRC (Strate & Syngal, 2005; Wells & Wise, 2017).   
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1.2.2 Hamartomatous Colon Cancer Syndromes  
  Hamartomatous polyposis syndromes are a group of uncommon conditions 
characterized by the development of intestinal hamartomas in childhood or in early 
adulthood. Peutz-Jeghers Syndrome, caused due to mutations in gene LKB1 
(STK11), is characterized by hamartomatous polyps in the entire gastrointestinal 
tract and other extra intestinal features such as mucocutaneous pigmentation and 
cancers of the breast, pancreas, thyroid and cervix. Juvenile polyposis caused due 
to mutations in the PTEN gene, consists of congenital abnormalities, including 
cardiac, craniofacial and bowel rotations and has about 10-40% penetrance. Other 
less common types include Cowden syndrome, Ruvalcaba– Myhre–Smith 
syndrome and Hereditary mixed polyposis (Strate & Syngal, 2005) 
 
1.2.3 Non-Polyposis Colon Cancer Syndromes 
   Non-polyposis colon cancer Syndromes include Lynch Syndrome (LS) and Muir 
-Torre syndrome. Lynch Syndrome accounts for about 3-5% of all CRC cases, 
making it the most common type of inherited colon cancer.  
 Individuals with LS have up to a 78% lifetime risk of developing CRC and 
typically present at an earlier age (less than 50 years of age). There is a high risk of 
developing cancers in extra colonic sites, such as the endometrium, renal pelvis, 
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ureter and small bowel. The condition is caused by mutations in the Mismatch 
repair genes (MMR) namely, MLH1, MSH2, MSH6 and PMS2(H. Lynch et al., 
2009; Vasen, 2007). LS is described in detail in the following sections. Muir -
Torre syndrome, a clinical variant of Lynch syndrome, is an autosomal dominant 
condition associated with skin lesions such as sebaceous adenomas, carcinomas, 
keratoacanthomas along with gastrointestinal cancers. It is associated with DNA 
mismatch repair mutations in genes MLH1 and MSH2 (Ponti & de Leon, 2005).  
 
1.3 Lynch Syndrome  
 
1.3.1 History of Lynch Syndrome  
    The history of Lynch Syndrome goes back to a little over 100 years, when Dr. 
Aldred Warthin, Chairman of the Department of Pathology at the University of 
Michigan in Ann Arbor, described the family of a Michigan seamstress who 
reported several early onset cancers in her family (Boland & Lynch, 2013; P. M. 
Lynch, 2017). Warthin created a pedigree of the family, indicating who did or did 
not develop cancer, making possible the first formal study of the condition. He 
named the family as ‘Family G’ and identified that there was “some influence of 
heredity on cancer” (Warthin, 1913). In 1925, he reported a further study on family 
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G, identifying higher incidence of colorectal and endometrial cancers, and the 
development of early onset cancer in the family (Warthin, 1925). There was not 
much development until the sixties, when Dr. Henry T. Lynch. MD, after whom 
the condition is named, identified the early onset cancers and the autosomal 
dominant inheritance pattern. After learning about Dr. Warthin’s efforts, Lynch 
arranged a reunion of the G family and termed the pattern of observed cancers the 
Cancer Family Syndrome. However, the use of that term was later discontinued to 
avoid confusion with Cancer Family Syndrome of Li and Fraumeni (now referred 
to as Li Fraumeni Syndrome) (P. M. Lynch, 2017). The term Hereditary Non-
Polyposis Colorectal Carcinoma was coined by Dr. Lynch himself in 1985. He 
coined the term to differentiate it from FAP, but the term was lengthy and excluded 
extracolonic manifestations (Boland, 2005). In 1973, Boland used the term Lynch 
Syndrome for the first time to honor the work of Dr. Lynch. He used the terms 
Lynch Syndrome I and II to differentiate between families with CRC only and with 
extra colonic cancers. It was after the understanding of the genetic basis, years 
later, that the term Lynch Syndrome was decided to be used for all spectrum of 
conditions with Microsatellite Instability (Boland, 2005) .  
   Continuing from this early work, the ground-breaking discovery in the history of 
LS was made in 1993, when an international consortium of scientists identified the 
genetic basis and the microsatellite instability characteristic of LS. The team was 
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working on samples from several large families from New Zealand and 
Newfoundland (P. M. Lynch, 2017).  Lauri Aaltonen identified significant linkage 
for LS on chromosome 2p, using the microsatellite marker, D2S12 (Aaltonen, 
Peltomaeki, Pylkkaenen, & Chappelle, 1993; Peltomaeki, Aaltonen, Pylkkaenen, & 
Chappelle, 1993). This breakthrough discovery was followed by intense and 
focused research effort in the western world which led to the identification of the 
four genes related to LS mutations as MLH1, MSH2, PMS1, and PMS2. Later, 
PMS1 was identified as not related to LS, and MSH6 was concluded as the fourth 
LS gene. (Miyaki et al., 1997)  
  During the late eighties and nineties, there were efforts to develop clinical criteria 
for the identification of Lynch Syndrome families. The International Collaborative 
Group on HNPCC (ICG-HNPCC) developed the Amsterdam criteria in 1990, later 
revised in 1998 as Amsterdam II criteria. Bethesda guidelines were established in 
1997 and revised in 2004. The limitations of these guidelines and criteria are well 
documented, and efforts continued to develop a system to identify all individuals 
with LS mutations irrespective of family history and clinical features. This 
ultimately led to the Jerusalem conference in 2010 and the EGAPP Working group 
(Evaluation of Genomic Applications in Practice and Prevention [EWG]) 
recommendations, and the introduction of Universal tumor Screening strategies 
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(Berg, Armstrong, & Botkin, 2009). These criteria are discussed in detail in later 
sections.  
 
1.4 Clinical features of Lynch Syndrome  
  LS is caused due to mutations in MMR genes and inherited in an autosomal 
dominant fashion. LS accounts for 3-5% of all cases of colorectal cancers and has a 
prevalence of about 1 in 440 in the general population (Rubenstein, Enns, 
Heidelbaugh, & Barkun, 2015). Chappelle et al. estimated the incidence of LS in 
the general population to be between 1 in 2000 to 1 in 660 and suggested it as one 
of the most common highly deleterious heritable conditions in man (de la Chapelle, 
2005).The cardinal features of Lynch Syndrome are given in table 1.1  
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Table 1.1 Cardinal features of Lynch Syndrome  
 
• Autosomal dominant inheritance.  
• Associated cancers: cancer of colorectum, stomach, ovary, ureter/renal 
pelvis, central nervous system, small bowel, hepatobiliary tract, skin 
(sebaceous adenoma) 
• Early age of cancer onset (Less than 50 years of age) 
• Features of colorectal cancer: predilection for proximal colon, improved 
survival, multiple colorectal cancers, poorly differentiated tumors and 
Crohn’s-like infiltration of tumor by lymphocytes 
• Features of adenomas: the numbers vary from one to a few, increased 
proportion of adenomas with a villous growth pattern, high degree of 
dysplasia, rapid progression from adenoma to carcinoma, proximal 
location and flat or sessile morphology  
• High frequency of microsatellite instability 
• Immunohistochemistry: loss of MLH1, MSH2, MSH6 and PMS2 protein 
expression. 
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1.5 Malignancies associated with Lynch Syndrome  
  Lynch Syndrome (LS) is associated with a spectrum of malignancies, beyond 
CRC alone. There is also increased risk for extracolonic malignancies including 
cancers of the endometrium, ovaries, stomach, small intestine, hepatobiliary, 
urinary tract and the Central Nervous System (Kanth, Grimmett, Champine, Burt, 
& Sammader, 2017). Some types of LS cancers may be more prevalent in some 
populations than others. For example, Korean HNPCC families were found to have 
a higher incidence of gastric and pancreatic cancers than Dutch HNPCC families, 
indicating some gene-environment interaction in LS cancer expression (Park, Park, 
Wijnen, & Vasen, 1999).  
 
1.5.1 Colonic Manifestations 
  CRC is the most common cancer associated with Lynch Syndrome. Lifetime risk 
of developing CRC in LS has been reported from 30-80% by various studies 
(Cohen & Leininger, 2014; Syngal et al., 2015). Early age of onset of CRC is a key 
feature of LS. The average age of onset has been described varyingly by different 
studies ranging from 44-48 (Cohen & Leininger, 2014; Kanth et al., 2017; Vasen, 
2007). Hampel et al. re-examined the penetrance of HNPCC by analysing the 
combined data set of several Finnish HNPCC families. In mutation-positive family 
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members, age of onset of CRC was found to be 53-68 years, much later than 
described in the literature. However, age of onset was 41-46 years considering only 
probands (i.e., those first identified in the family). It was also found that the 
lifetime risk was lower than earlier reported (Hampel, Stephens et al., 2005). The 
CRCs in LS are associated with proximal colonic involvement. Seventy percent of 
the colonic malignancies in LS arise proximal to splenic flexure. A small adenoma 
can develop into a malignant tumor in a short time of two to three years, compared 
to eight to ten years in sporadic cases. This accelerated carcinogenesis leads to a 
higher incidence of interval cancers in LS carriers (Jass et al., 2002; Rijcken, 
Hollema, & Kleibeuker, 2002; Vasen, Nagengast, & Khan, 1995). Interval CRC is 
defined as CRC diagnosed after a cancer-detecting test in which no cancer was 
detected and before the date of the next suggested test (Sanduleanu et al., 2015). 
CRC tumors in LS are often poorly differentiated, with an excess of mucoid and 
signet cell features. LS CRCs tend to be diploid in nature and show Chron’s-like 
reaction and lymphocyte predominance (Jass et al., 2002). Synchronous and 
metachronous cancers are another key feature of LS. Synchronous tumors are 
defined as a second primary tumor identified at the same time or within six months 
of diagnosis of the first primary tumor. Metachronous tumors are diagnosed after 6 
months or later, in a different part of the organ (H. Lynch et al., 2009; Vasen, 
2007).  
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1.5.2 Extra Colonic Manifestations 
  Lynch Syndrome (LS) is associated with increased risk of several extra colonic 
malignancies. Endometrial carcinoma in women is the most common extracolonic 
manifestation of LS. The lifetime risk of developing endometrial carcinoma in 
female mutation carriers is 30-60% (Vasen, 2007). They have an age of onset ten 
years earlier than the general population, which is between 50-60 years of age 
(Cramer, 2012; Pessoa et al., 2014). The histopathologic features related to MMR 
mutation include solid-cribriform growth, mucinous differentiation and necrosis. 
Mutations in MSH6, MLH1 and MSH2 are found to be associated with endometrial 
carcinoma, with the MSH6 and MSH2 having the highest risk of up to 44% (Cohen 
& Leininger, 2014).  
  The lifetime risk of developing ovarian cancer is 6.7% - 12% with a slightly 
higher risk in MSH2 carriers (Cohen & Leininger, 2014). Gastric cancer occurs in 
up to 13% of cases but is more common in the Asian countries of Japan, South 
Korea and China (Park et al., 1999). Small bowel cancers and cancers of the 
ureter/renal pelvis occur less frequently in up to 6% of LS cases.  It was found that 
brain cancers were the third most frequent cause of cancer death in LS (6.7%) after 
CRC (50.3%) and endometrial carcinoma (6.7%) (de Jong et al., 2006). 
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1.6. Genetic Basis of Lynch Syndrome  
   Lynch syndrome occurs due to mutations in the Mismatch Repair (MMR) genes. 
The Mismatch repair proteins detect and repair the errors that may occur after 
DNA replication in cells. Therefore, it plays an important role in maintaining the 
genetic integrity in somatic cells where cell turnover is very rapid, such as the 
intestinal epithelium. Defective MMR genes can result in the accumulation of 
DNA replication errors in somatic cells. There are five MutS genes (MSH2, MSH6, 
MSH3, MSH4, and MSH5) and four MutL genes (MLH1, PMS2, PMS1, and 
MLH3) in human cells which can mediate mismatch repair in various 
heterodimeric combinations (Peltomäki, 2016). Among these four are conclusively 
associated with Lynch Syndrome, namely MLH1, MSH2, MSH6 and PMS2 
(Peltomäki, 2016). There are more than 5000 pathogenic variations of these genes 
associated with LS as listed in the International Society for Gastrointestinal 
Hereditary Tumors (InSiGHT) database (https://www.insight-
group.org/syndromes/lynch-syndrome/) (Peltomäki, 2016; Plazzer et al., 2013). 
Among these, 70-90% are attributed to MLH1 and MSH2 and the remaining 10-
30% to MSH6 and PMS2. Up to 3% of LS is associated with the EPCAM gene, 
whose mutations will result in the hypermethylation of MSH2 promoter, resulting 
in Lynch Syndrome. (Cohen & Leininger, 2014; Tutlewska, Lubinski, & 
Kurzawski, 2013) 
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     The occurrence of malignancy in Lynch Syndrome follows Knudson’s two hit 
hypothesis of carcinogenesis in hereditary conditions (Knudson, 1971). The 
inheritance of the faulty gene constitutes the first hit, and the somatic mutations 
make the second hit resulting in cancer. The mutations in the MMR genes’ errors 
lead to the carcinogenesis in LS. There is evidence to suggest that in Lynch 
Syndrome cancers, both hits could be genetic or epigenetic (Peltomäki, 2014). The 
epigenetic mechanisms identified so far include deletion of the EPCAM gene 
combined with hypermethylation of MSH2 promoter, and methylation of MLH1 
(Cohen & Leininger, 2014; Peltomäki, 2014; Tutlewska et al., 2013). Lifestyle and 
environmental factors have also been implicated in Lynch syndrome, suggesting 
possible areas where primary and secondary preventive strategies can be employed 
(Park et al., 1999; van Duijnhoven et al., 2013). 
   
1.7 Molecular Basis of Lynch Syndrome  
   Microsatellites are repetitive DNA sequences of either a single nucleotide 
(mono) or more than one nucleotide (bi-, tri-, tetra-, or penta-). There are over 
500,000 microsatellites in the human genome (Chapelle & Hampel, 2010; de la 
Chapelle, 2003). Normally, the number of repeats in a microsatellite will be the 
same for every cell. When the microsatellites gain or lose repeat units in one or 
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two alleles and vary between cells, it is said to have Microsatellite Instability or 
MSI (Chapelle & Hampel, 2010). Usually they can be detected if they are present 
in a relatively high number of cells, which is typical in the case of a neoplasm. 
MSI is the hallmark phenotype in Lynch Syndrome and was identified by Aaltonen 
et al. in 1993 (Aaltonen et al., 1993). MSI can be detected in over 90% of all 
Lynch Syndrome cases, but in 15% of all CRC cases as well (H. T. Lynch et al., 
2006). MSI in sporadic CRC occurs due to hypermethylation of the MLH1 
promoter region (Aaltonen et al., 1998; H. T. Lynch et al., 2006). Identification of 
MSI can be used as a screening test for Lynch Syndrome in patients diagnosed 
with CRC.  
 
1.8 Molecular screening tests for Lynch Syndrome  
 
1.8.1 Microsatellite instability testing (MSI testing) 
   MSI can be identified by testing for several markers, including mononucleotide 
repeats or for higher nucleotides. The National Cancer Institute guidelines for 
determination of MSI in colorectal cancers recommended a panel of five markers 
for testing MSI known as the Bethesda panel. They include two mononucleotide 
repeats (BAT26, BAT25) and three dinucleotide repeats (D2S123, D5S346, 
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D17S250) (Boland et al., 1998). Depending on the number of markers showing 
instability, the result can be categorized into High Instability MSI-H, if there is 
MSI in two or more markers (>30-40%), Low Instability MSI-L if there is 
instability in less than 2 markers (<30%) and no Instability, MSS (Microsatellite 
Stability) in cases where there is no instability detected (Boland et al., 1998).  
There are different test kits available using varying type and number of markers. 
Murphy et al. compared the most frequently used one, the Microsatellite Instability 
Analysis System (Promega Corp), with the Bethesda panel and found 85% 
concordance between the two systems (Murphy et al., 2006). The EGAPP Working 
Group (EWG) found adequate evidence showing 90.2% specificity for MSI testing 
(Berg et al., 2009). There was also adequate evidence showing that the sensitivity 
of MSI testing was 89% for MLH1 and MSH2 mutations, and 77% for MSH6 
mutations (Palomaki, Mcclain, Melillo, Hampel, & Thibodeau, 2009). 
Microsatellite instability testing can be a useful tool in identifying individuals at 
risk of having Lynch Syndrome. 
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1.8.2 Immunohistochemistry  
  
     An alternative to MSI testing is the use of Immunohistochemistry testing (IHC) 
on resected tumor tissue and biopsy samples. Immunohistochemistry testing 
employs monoclonal and polyclonal antibodies to visualize the presence or 
absence of MMR proteins using fluorescence or similar methods. Loss of one or 
more of the MMR proteins suggests the possibility of mutation in the associated 
genes, potentially indicative of LS. In 1996, Leach et al. developed monoclonal 
antibodies for MSH2, paving the way for IHC analysis in MMR deficiency (Leach 
et al., 1996). Thibodeau et al. later examined MSH2 and MLH1 mutations using 
Immunohistochemistry testing (Thibodeau et al., 1996). Several reports of the 
involvement of MSH6 mutations were subsequently published. MLH1 and MSH2 
protein expression in IHC in CRC tumors were studied and IHC testing was found 
to be a valuable tool for detecting possible LS mutations in young patients (Paraf et 
al., 2001). Stone et al. compared Microsatellite stable (MSS) and Microsatellite 
instable tumors using IHC and discussed the potential of IHC in the detection of 
MMR deficiency in routine clinical practice (Stone, Robertson, & Houlston, 2001). 
CRC patients were tested for germ-line mutations MLH1, MSH2, and MSH6 by 
employing a mixed method of clinical measures and IHC analysis, and a positive 
predictive value of 80 percent and a sensitivity of 62 percent for mutation carriers 
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were estimated (Barnetson et al., 2006). In another study, paraffin embedded tumor 
samples of 85 individuals with CRC collected from 1979 to 1999 were examined 
using IHC for MSH2, MSH6 and MLH1 mutations. The sensitivity for predicting a 
pathogenic mutation was 89%, despite a non-standardized fixing of the tissue 
samples (Hendriks et al., 2002). The Evaluation of Genomic Applications in 
Practice and Prevention (EGAPP) Working Group (EWG) conducted a series of 
extensive reviews to evaluate various screening methods and their clinical validity. 
The sensitivity of IHC in identifying MMR was found to be 78% (65-88), MSH2 to 
be 80% (62-90), MSH6 to be 74 % and the overall sensitivity to be 77% (69-84). 
The specificity of IHC testing was found to be 88.8% with an adequate level of 
evidence (Berg et al., 2009; Palomaki et al., 2009). The sensitivity of IHC as an 
indication of MMR mutation has been estimated as 83%, with 90% specificity 
(Chubak, Heald, & Richard, 2011; South et al., 2009).  
  There are several advantages for Immunohistochemical screening for Lynch 
Syndrome. Firstly, IHC is readily available in most laboratory facilities and is 
therefore convenient for pathologists as well as patients in terms of accessibility. 
Secondly, IHC is thought to be more cost efficient than MSI screening. IHC was 
found to be three times less expensive than MSI testing with no change in 
sensitivity (Debniak et al., 2000). Thirdly, it has been shown that IHC could be 
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helpful in identifying MMR missed by MSI testing (Shia, 2008). Studies have 
shown that the sensitivity and specificity of IHC testing is similar or higher to MSI.  
   However, there is no scientific consensus yet as to which of these testing 
methods should be used in identifying patients at risk of having LS, IHC or MSI 
testing. Existing guidelines recommend the use of either of these methods for CRC 
tumor screening for LS (Berg et al., 2009).  
 
1.9  Diagnostic and Clinical Criteria for Lynch syndrome  
  Families at risk for developing Lynch syndrome are conventionally identified 
based on clinical and family history, such as those used in the Amsterdam I and II 
criteria and both the original and revised Bethesda guidelines. In recent years, 
various predictive models and Universal tumor screening strategies have been 
suggested to help identify more individuals at risk of having Lynch syndrome. 
Individuals tested fulfilling these criteria or tested positive using screening tests 
would undergo germline analysis to diagnose Lynch Syndrome.  
 
1.9.1 Amsterdam Criteria  
     The International Collaborative group on HNPCC developed a set of guidelines 
in 1990 to help identify families at risk of having LS. They came to be known as 
Amsterdam criteria, after the venue of the meeting. To be identified as at risk, an 
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individual should have met all three criteria: 1) At least three relatives should have 
histologically verified colorectal cancer; one of them should be a first degree 
relative to the other two. Familial adenomatous polyposis should be excluded. 2) 
At least two successive generations should be affected. 3) In one of the relatives, 
colorectal cancer should be diagnosed under 50 years of age (Vasen, Mecklin, 
Khan, & Lynch, 1991). The extracolonic manifestations of LS were not taken into 
consideration and the Amsterdam criteria failed to identify some LS families. 
Therefore, in 1999, ICG-HNPCC issued a revised set of diagnostic guidelines, 
known as the Amsterdam II criteria, including the extracolonic cancers namely 
endometrium, small bowel, ureter or renal pelvis (Vasen, Watson, Mecklin, & 
Lynch, 1999) 
  The validity of Amsterdam criteria I and II has been widely studied. In a large 
cohort of CRC patients in Scotland, Barnetson et al. tested 890 patients for MMR 
mutations (MLH1, MSH2 and MSH6) using DNA analysis. They found that 52% of 
participants who were carrier-positive did not fulfil the ACII criteria. (Barnetson et 
al., 2006). Vasen et al. reviewed the literature in 2007 and found that only 41% of 
the mutation carriers fulfilled the Amsterdam criteria (Vasen, 2007). Syngal et al. 
found that the sensitivity and specificity of ACI were 61% and 67%, and that of 
ACII were 72% and 50%, respectively in MLH1 and MSH2 carriers (Syngal, Fox, 
Eng, Kolodner, & Garber, 2000). While better than ACI, ACII still missed 22% of 
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the mutations, thus excluding those patients and their families from surveillance 
and access to confirmatory genetic testing. Although Amsterdam Criteria were 
successful in the detection of HNPCC families, their limitation in identifying 
MSH2 and MLH1 mutations make them less efficient for identifying all high-risk 
individuals (Syngal et al., 2000).  
 
1.9.2 Bethesda Guidelines.  
  By 1996, the association of LS with Microsatellite Instability and MMR 
mutations was known to the scientific community. The Bethesda guidelines were 
developed to identify the individuals who needed MSI testing. Later in 2004, the 
Revised Bethesda guidelines were introduced (Rodriguez-Bigas et al., 1997; Umar 
et al., 2004). The Bethesda and the revised guidelines are shown in Table 1.2.  
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Table 1.2 Bethesda and the Revised Bethesda criteria for Hereditary 
Non-Polyposis Colorectal Cancer (Lynch Syndrome) 
Bethesda guidelines  
1.Individuals with cancer in families that meet the Amsterdam criteria. 
2.Individuals with two HNPCC-related cancers, including synchronous and 
metachronous colorectal cancers or associated extracolonic cancers. a  
3.Individuals with colorectal cancer and a first-degree relative with 
colorectal cancer and/or HNPCC related extracolonic cancer and/or a 
colorectal adenoma; one of the cancers diagnosed at age < 45years, and the 
adenoma diagnosed at age < 40 y. 
4.Individuals with colorectal cancer or endometrial cancer diagnosed at age 
<45 y. 
5.Individuals with right sided colorectal cancer with an undifferentiated 
pattern (solid/cribriform) on histopathology diagnosed at < 45 y. b 
6.Individuals with signet-ring-cell-type colorectal cancer diagnosed at age 
<45 y. c 
7.Individuals with adenomas diagnosed at age <40 y. 
Revised Bethesda guidelines  
1.Colorectal cancer diagnosed in a patient <50 years of age. 
2.Presence of synchronous, metachronous colorectal, or other Lynch 
syndrome-related tumors, regardless of age. d 
3.Colorectal cancer with MSI-H e histology f diagnosed in a patient <60 
years of age. 
4. Patient with colorectal cancer and a first-degree relative with a Lynch 
syndrome-related tumor, with one of the cancers diagnosed under age 50 
years. 
5. Patient with colorectal cancer with two or more first-degree or second-
degree relatives with a Lynch syndrome-related tumor, regardless of age. 
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a endometrial ovarian, gastric, hepatobiliary, or small bowel cancer or transitional cell carcinoma of the 
renal pelvis or ureter.  
b Solid/cribriform defined as poorly differentiated or undifferentiated carcinoma comprised of irregular 
solid sheets or large eosinophilic cells and containing small gland-like spaces.  
c Composed of >50 % signet ring cells.  
d Hereditary nonpolyposis colorectal cancer (HNPCC)-related tumors include colorectal, endometrial, 
stomach, ovarian, pancreas, ureter and renal pelvis, biliary tract, and brain (usually glioblastoma as seen 
in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir–Torre syndrome, 
and carcinoma of the small bowel.  
e MSI-H = microsatellite instability–high in tumors refers to changes in two or more of the five National 
Cancer Institute-recommended panels of microsatellite markers. 
f Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring 
differentiation, or medullary growth pattern. 
 
   A handful of studies have evaluated the Bethesda guidelines. According to a 
review by Vasen et al., 89% of the mutation carriers fulfilled Bethesda guidelines 
(Vasen, 2007). Syngal et al. classified 70 LS families by Amsterdam and Bethesda 
guidelines to estimate their clinical validity. The sensitivity and specificity of the 
Bethesda guidelines were estimated as 94% and 25% respectively, showing the 
low specificity (Syngal et al., 2000). However, the revised guidelines were found 
to have a sensitivity of 94% and specificity of 49%. Studies have shown that using 
Bethesda guidelines alone could lead to mutation positive individuals being ruled 
out. In a study of 870 CRC patients, among the participants who fulfilled Bethesda 
guidelines, 62% tested negative for a MLH1 or MSH2 mutation, (Barnetson et al., 
2006). Similarly, in a French study, it was found that the revised Bethedsa 
guidelines failed to detect two of eight probands, while molecular testing identified 
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all eight of them with no significant increase in workload (Julié et al., 2008). A 
later age of onset of cancers than earlier reported was observed among two cohorts 
of Dutch HNPCC families, indicating that if the revised Bethesda guidelines were 
employed, some patients would still be missed (Hampel et al., 2005).  
 
1.9.3 Predictive models 
 Predictive models are tools developed based on regression models using clinical 
and family history to predict the probability of a germline mutation in an 
individual. They calculate a “numerical risk” or likelihood of having MMR 
mutations. A handful of these evidence-based models have been developed and 
validated for Lynch Syndrome. One of them, the PMMRpro, developed by Chen et 
al. predicts the risk of MLH1, MSH2 and MSH6 mutations (Chen et al., 2006). A 
clinically-driven predictive model has been developed to predict DNA mismatch 
repair mutations in MLH1, MSH2 and MSH6 (Barnetson et al., 2006) called 
MMRPredict. This model has the best specificity (90%) among predictive models 
(Giardiello et al., 2014). The PREMM 1,2,6 (Kastrinos, 2011) model which 
predicts risk of MLH1, MSH2 and MSH6 germline mutations has a sensitivity of 
90% and specificity of 67%. (Giardiello et al., 2014; Kastrinos, 2011). The model 
has recently been expanded to PREMM5 to include PMS1 and EPCAM mutations 
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also (Kastrinos et al., 2017). However, because these predictive models rely at 
least in part on family and clinical history, much like the Amsterdam and Bethesda 
criteria, they have similar limitations.  
  Identification of individuals and families with germline mutations in the MMR 
genes remains a critical clinical and public health challenge. The limitations and 
poor performance of the criteria based on family history led to the emergence of 
universal tumor screening recommendations.   
 
1.10 Universal tumor Screening for Lynch Syndrome 
   Universal tumor screening for Lynch Syndrome (LS) refers to the strategy of 
screening every newly diagnosed CRC patient using MSI or IHC testing, 
irrespective of family history. For those testing positive in the initial screen, 
germline testing is then recommended to confirm the diagnosis of LS. Hampel et 
al. conducted a study to evaluate various screening methods for LS by performing 
MSI testing on 1066 CRC patients in Ohio. IHC analysis was done for the patients 
with high microsatellite instability, which was followed by germline mutational 
analysis. It was concluded that large scale screening of CRC patients was a feasible 
option and the authors recommended MSI screening for every newly diagnosed 
CRC patient (Hampel, Frankel et al., 2005). A workshop was held in Jerusalem in 
2009 to discuss the screening and management of Lynch Syndrome; subsequently, 
 27 
 
the Jerusalem guidelines were published. It was recommended to screen all CRC 
patients younger than 70 years of age for LS mutations, (Boland & Shike, 2010). 
The universal screening strategy implies the screening to be ‘automatic’ or 
reflexive in nature, where all newly diagnosed CRC patients are automatically 
tested. The screening strategy is also referred to as reflex testing. (Beamer et al., 
2011). The Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) working Group (EWG), based on a review of available evidence on 
population level screening and outcomes, found sufficient evidence to recommend 
genetic testing to detect LS in all newly diagnosed CRC patients (Berg et al., 2009; 
Palomaki et al., 2009). This recommendation by EWG sparked a movement 
towards universal tumor screening for identifying at risk individuals as a routine 
practice, which was followed by several studies exploring its feasibility.  
  In 2008, a study was conducted comparing screening based on revised Bethesda 
guidelines and molecular screening using MSI for all patients. It included 214 
patients, among which Bethesda guidelines failed to detect two of the eight 
probands, whereas the MSI detected all mutations. It was concluded that the 
universal tumor screening strategy using MSI testing was more effective in 
identifying at risk individuals LS mutations and that the germline testing workload 
was only slightly higher for such screening (Julié et al., 2008).  
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   In a prospective multicenter study of 1137 CRC patients, MSI testing and IHC 
analysis were conducted on all 1117 patients; germline mutation analysis followed 
for those patients with MSI or MMR deficiency. Among the participants, 83% 
referred to counselling after testing positive had not fulfilled any family history-
based criteria. The LS incidence in the study population was 4.5%, concordant 
with the existing literature, and routine MSI screening of every newly diagnosed 
CRC patient up to the age of 70 was suggested (Van Lier et al., 2012). 
  Universal tumor screening for LS and revised Bethesda guidelines were also 
compared in a Spanish cohort. IHC or MSI testing was performed on 2093 CRC 
patients, and those with loss of MMR expression or high MSI were followed up 
with genetic testing. Among the patients identified with LS mutations, 14.3% did 
not fulfill revised Bethesda guidelines and would have been missed if family 
history-based criteria were used. Universal tumor screening strategy with 
immunohistochemistry or MSI testing was found to be more effective (Perez-
Carbonell et al., 2012).  
  Similarly, Bethesda guidelines failed to detect up to 37% of potential LS-affected 
individuals in a prospective study involving 1040 CRC patients (Canard et al., 
2012). A pooled data analysis of four cohorts from the US and Finland assessed a 
strategy of germline mutation testing for MSI positive individuals in 10,019 CRC 
patients. Germline mutational analysis was done for those probands with positive 
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MSI, and it was found that 3.1% of all the participants carried LS-associated 
mutations. Only universal screening had 100% sensitivity and was concluded to be 
the most effective compared to alternative strategies including Bethesda guidelines 
and Jerusalem criteria (Moreira et al., 2012). Thus, evidence from several large 
studies shows that universal tumor screening strategies using MSI or IHC is 
beneficial in identifying patients with Lynch Syndrome. Based on these studies and 
the recommendation from the EGAPP Working Group (EWG), universal tumor 
screening for Lynch Syndrome has been recommended by a number of 
international organizations and health systems.  
   The United States Multi-Society Task Force (USMSTF) for colorectal cancer 
endorsed MMR deficiency testing for all CRC cases using IHC testing for MLH1, 
MSH2, PMS2 or MSH6 proteins or using MSI testing. They recommend testing for 
all CRC cases, or in CRC patients diagnosed at younger than 70 years of age, and 
in individuals older than 70 who have a family history (Giardiello et al., 2014). The 
National Comprehensive Cancer Network (NCCN) also recommends screening all 
CRC patients, or CRC under 70 years and in those over 70 who meet the Bethesda 
guidelines, using either IHC or MSI (Provenzale & Gupta, 2015). The American 
Gastroenterological Association Institute and the American College of 
Gastroenterology recommend screening for LS in patients diagnosed with CRC 
using MSI or IHC (Rubenstein et al., 2015; Syngal et al., 2015). One of the 
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genomics objectives of the initiative of Healthy People 2020 is to increase the 
number of patients diagnosed with CRC who undergo screening for LS in 
accordance with the EGAPP and US Task Force recommendations (Green, Dotson, 
Bowen, Kolor, & Khoury, 2015). The National Society of Genetic Counselors and 
the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint 
Practice Guideline recommends MSI or IHC testing for all newly diagnosed CRC 
and endometrial cancer patients (Weissman et al., 2012). Additionally, similar 
strategies were also recommended by the National Institute of Health and Care 
Excellence (NICE) (Newland, 2017).  
   Since the recommendations of EGAPP and USMSTF, there has been a trend 
toward universal tumor screening in the US. The Lynch Syndrome Screening 
Network (LSSN) was initiated in 2011 with 35 participating institutes with aim to 
promote universal screening and to facilitate institutions to implement screening 
programs (Mange, 2015). In the United States, even though Lynch Syndrome 
screening protocols for CRC and endometrial carcinomas are prevalent and have 
been increasing in recent years (Cohen, 2014; Cragun et al., 2014), there is still 
room for improvement. A survey of cancer centers in the US found that only 70% 
of the National Cancer Institute–designated Comprehensive Cancer Centers (NCI-
CCCs) were utilising a universal reflex testing strategy (Beamer et al., 2011). In 
Canada, an integrated approach in LS screening among CRC patients is lacking 
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(Bombard et al., 2017). A survey of pathologists across Canada suggests that most 
of the MMR deficiency tests are requested by clinicians and highlights the lack of 
standardized guidelines regarding LS screening (Kalloger et al., 2012). Lynch 
Syndrome is under-recognized, with centres still relying on family history-based 
Amsterdam and Bethesda guidelines to identify at risk individuals (Pi, Nap-Hill, 
Telford, & Enns, 2017). 
   In Newfoundland, where the incidence of familial CRC is very high, it was found 
that a screening approach based on family history was inefficient. For 48% of 
incident cases, family history information was not available or provided, resulting 
in failure to assess those cases for LS risk (Parfrey et al., 2017). These studies 
suggest a lack of standardized universal tumor screening guidelines and 
irregularities in practice, meaning some individuals at risk of having LS remain 
unidentified. This is a crisis not only at a patient level where adequate risk 
identification and preventive surveillance are not provided due to a lack of 
screening, but also at population level, with high mortality and morbidity of LS-
associated malignancies.  
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1.10.1 Economic feasibility of universal tumor screening.  
  A universal tumor screening strategy involves testing a large number of 
individuals compared to any other screening criteria. In any such large-scale 
program, cost effectiveness and economic feasibility are important issues that need 
to be addressed. Evidence from the literature suggests that population-level 
screening is a cost-effective method in identifying LS carriers. In an American 
cost-effectiveness study, it was found that the incremental cost effectiveness ratios 
for universal tumor screening for LS using IHC or MSI ranged from $12,332 to 
$49,272 per life year saved compared to no testing, and from $18,778 to $85,391 
per life year compared to screening based on age. IHC screening was found to 
have 40% lower costs compared to MSI testing. IHC screening followed by 
germline testing was found to be the most effective strategy, and it was 
concluded that universal tumor screening of all newly diagnosed CRC patients 
was a cost-effective option in the country (Mvundura, Grosse, Hampel, & 
Palomaki, 2010). In another feasibility analysis of various screening strategies for 
LS, including family history-based and germline testing, it was found that 
screening of newly diagnosed CRC patients could provide clinical benefits at an 
acceptable cost. The cost effectiveness was dependent on screening of the relatives 
and their risk reduction strategies. IHC testing with subsequent germline testing in 
positive individuals, was the most effective strategy. MSI testing followed with 
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germline testing in positive individuals was found to be the second-best strategy. It 
was also found that limiting the screening strategy to patients younger than 50 
presented a more cost-effective option, but at the risk of having older LS patients 
being left undetected (Ladabaum et al., 2011). In a systematic review, MSI testing 
and IHC testing were both cost effective strategies in screening for LS. The cost 
effectiveness is dependent on various factors such as utilization of genetic testing 
and screening of relatives to provide their risk reduction strategies (Di Marco et al., 
2017; Grosse, 2015; Snowsill et al., 2014; Snowsill et al., 2017).  
  
1.10.2 Preventive and therapeutic implications of screening  
  Screening for LS mutations among CRC patients has several benefits to the 
patients themselves and their family members. Firstly, understanding genetic risk 
of LS has prognostic and therapeutic implications for the patients themselves. 
Individuals with LS are at higher risk of developing several extracolonic 
malignancies. In patients with LS, therefore, frequent cancer surveillance and 
screening at younger ages (e.g., colonoscopic surveillance) may be required in 
order to detect these malignancies at an early stage. Options for preventive 
procedures, including hysterectomy or salpingo-oophorectomy for affected 
females, could help patients in reducing cancer risk (Hampel, 2018). Secondly, 
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microsatellite instability status of CRC tumors could have prognostic implications 
for the patients (Gryfe et al., 2000; Kang et al., 2018). MSI-CRCs have been found 
to have a better prognosis and overall survival (HR= 0.69; 95% CI: 0.56 to 0.85) 
compared to MSS CRCs (Popat, Hubner, & Houlston, 2005). Thirdly, therapeutic 
implications of MSI status have been highlighted by a handful of studies. It has 
been shown that patients with high MSI status had a better survival and prognosis 
with surgery alone, compared to surgery and adjuvant chemotherapy with 
fluorouracil (Popat et al., 2005; Ribic et al., 2003; Smyth et al., 2017). 
Furthermore, recent evidence about the clinical benefits of immunotherapeutic 
agents such as pembrolizumab in MMR deficient tumors, shows the importance of 
identifying the genetic and molecular status of CRC patients (Hampel, 2018; Le et 
al., 2015). Thus, there are several benefits for CRC patients themselves in 
determining MSI or MMR deficiency.  
   While the benefits to the patients are important, the identification of at risk 
individuals through cascade testing of relatives has implications for current and 
future generations and confers a public health benefit. Evidence suggests a higher 
likelihood of relatives undergoing cancer screening and surveillance procedures if 
the LS mutation status of the patient is known (Bonis, Trikalinos, & Chung, 2007). 
At risk family members who undergo regular colonoscopic surveillance have lower 
incidence of CRC, lower CRC mortality and increased overall survival. It has been 
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shown that colonoscopic surveillance can decrease CRC incidence by 59-62%, 
preventing a conservative estimate of up to 5000 colon cancer cases in the US 
(Bellcross, 2012). CRC-associated mortality rates are reduced in those patients 
who undergo regular colonoscopic screening. Additionally, LS patients who 
underwent regular cancer surveillance were found to have an increased life 
expectancy by 23 years, compared to no surveillance (Stupart, Goldberg, Algar, & 
Ramesar, 2009). The extent of these benefits is directly associated with the 
efficiency of screening programs in identifying at risk individuals, as well as the 
extent to which their family members are screened for LS and subsequently 
followed up with cancer surveillance. 
   Universal tumor screening has been shown to benefit at risk individuals (Berg et 
al., 2009). Perspectives of key stakeholders on universal tumor screening are 
critical since the success of screening programs is reliant on patient and family 
engagement with follow-up diagnostic testing and adherence to cancer surveillance 
behaviors recommended for high-risk family members. 
    In 1968, “Principles and Practice of Screening” from the World Health 
Organization introduced a set of ten criteria to be met by screening programs 
before being established as a public health measure (Wilson & Jungner, 1968). 
Universal screening for LS meets most of the original public health screening 
criteria. Notably, one of the Wilson-Jungner criteria that is not met was, “The test 
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should be acceptable to the population” (Cragun, DeBate, & Pal, 2015). Cragun et 
al. argued that a lack of research about public perceptions of tumor screening 
precluded meeting this criterion. A newer set of population screening criteria was 
introduced decades later to reflect the scientific advancements and change since 
Wilson and Jungner’s seminal work (Andermann, Blancquaert, Beauchamp, & 
Déry, 2008).  One of the newer criteria for population screening suggests that the 
program should ensure informed choice and patient autonomy. Since patient 
perceptions on informed consent for universal screening is relatively under-
researched and the current practice is non-requirement of a consent, this criteria is 
not met (Cragun et al., 2015). The following sections outlines these areas, 
overviews the available literature and identifies the gap in existing knowledge.  
   
1.11 Perspectives of stakeholders regarding benefits and barriers 
   The key stakeholders of a universal tumor screening program include CRC 
patients and healthcare providers including surgeons, pathologists, genetic 
counsellors, gastroenterologists, and primary care providers. The studies exploring 
their perspectives are limited in number but aim at highlighting the facilitators and 
barriers of universal screening, consent protocols and the role of communication of 
genetic risk.  
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   1.11.1 Perspectives of healthcare providers  
  The healthcare professionals who would be involved in a universal tumor 
screening program for LS range from primary care physicians, surgeons, 
gastroenterologists, oncologists, pathologists and genetic counselors. Their 
perspectives would be crucial in establishing evidence-based guidelines and policy 
initiatives regarding the program. In a qualitative study, Bombard et al. 
interviewed 27 Canadian health providers. The participants were generally in 
favour of a universal tumor screening program, but identified some challenges, 
including lack of patient awareness, longer wait times, lack of genetic counselor 
resources and the need for a co-ordinated, ongoing system of cancer surveillance. 
The study also noted the lack of a universal practice guideline regarding LS 
screening across the country (Bombard et al., 2017). In the US, where universal 
tumor screening is becoming routine, genetic counselors identified barriers to 
implementing the program such as collaboration of stakeholders, cost, and 
convincing the medical staff about the necessity of the program (Cohen, 2014). A 
survey of clinical and laboratory staff revealed support for universal screening but 
noted barriers such as the need for infrastructural support and effective 
interdepartmental collaboration and communication (Schneider et al., 2015). Other 
identified barriers to tumor screening included the need and process for informed 
consent, the psychosocial burden for patients with cancer and undergoing 
 38 
 
treatment, and barriers related to communication between healthcare providers and 
family members (Hall, 2010).  
 
1.11.2 Need for informed consent  
  Informed consent requires that patients understand the risks, benefits and 
alternatives to the procedure or test prior to the test or procedure, enabling them to 
make informed decisions about their health in accordance with their values (Annas, 
1977; Faden, 1986). Explicit informed consent is required prior to colon cancer 
screening or diagnostic procedures, including colonoscopy. However, there is no 
similar consent requirement for testing biopsy samples or resected tissue samples 
(Feld, 2002). The consent model often used in this situation is of implied consent. 
Germline genetic tests require explicit informed consent because of their 
implication in the patient’s, as well as their family’s health and future (Feld, 2002). 
There are no detailed guidelines available on consent for tumor testing for LS and 
it is a topic of debate in the literature. (Beamer et al., 2011; Bombard et al., 2017; 
Shipman, Arribas-Allyon, Murray, & Gaff, 2013). The reflexive or automatic 
nature of the universal screening has implications for the role of informed consent 
and its protocol. One of the arguments is that MSI testing can be considered as a 
genetic test, and as such, the EGAPP Working Group (EWG) suggests the use of 
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informed consent prior to MSI testing, whilst noting the contrasting views from the 
literature. IHC testing is not viewed as ‘genetic testing’ and thus, informed consent 
is not a requirement (Berg et al., 2009). Some authors disagree with this, 
suggesting IHC testing has more in common with genetic tests because of the 
information the test provides (Chubak et al., 2011). Chubak et al. conclude that 
explicit informed consent is not required for MSI testing because the testing does 
not affect patients in “potential harmful ways” that necessitates an informed 
consent. Bombard et al., in a survey among healthcare providers, similarly found 
that healthcare providers did not see the need for consent for universal tumor 
screening but endorsed an opt-out option for further germline mutation testing. To 
date, the consent protocols regarding universal tumor testing are not well 
established and the issue of consent is widely debated (Bombard et al., 2017; 
Chubak et al., 2011; Janet & Marc, 2011; Shipman et al., 2013).  
 
1.11.3 Perspectives of patients 
  Very few studies have explored the perspectives of patients regarding universal 
tumor screening, but existing literature suggests a generally favorable attitude. A 
telephone survey of 145 CRC patients who consented to screening were followed 
up with a second questionnaire after results of the screening test were provided. 
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Participants had a positive attitude towards screening, understood the benefits of 
testing and were willing to communicate the results to family members and health 
care providers. Participants of that study had low prior knowledge about screening 
and LS. In a follow up survey after screening and germline testing, most of the 
patients were consistent with their initial answers and had shared their results with 
family members. Though the study was conducted among patients who consented 
to participate in screening, and therefore did not necessarily reflect the attitudes of 
CRC patients in general, the findings of the study establish the significance of 
understanding the patient perspective (Hunter et al., 2015; J. Hunter et al., 2017). 
In a cross-sectional survey of 91 CRC patients, it was found that 67% of the 
participants expressed interest in genetic screening. The benefits of screening were 
found to be more important to patients compared to barriers, among which the 
main barrier was economic (Cragun, Malo, Pal, Shibata, & Vadaparampil, 2012). 
In another survey among 125 individuals who met the Bethesda criteria, it was 
found that patients generally had low levels of knowledge about MSI testing but 
had an overall positive attitude about screening (Manne S., Chung D., & Weinberg 
D., 2007). To our knowledge, no research has explored the opinions of patients in 
Canada about universal tumor screening for LS.  
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  In all, this small body of literature highlights gaps in our understanding of both 
patient and healthcare provider perspectives about universal tumor screening, as 
well as the lack of data from a Canadian context.  
 
 1.12 Summary  
  Lynch Syndrome is the most common cause of hereditary colon cancer, affecting 
3-5% of all CRC cases. Universal tumor screening for LS among CRC patients 
using MSI testing or IHC is recommended by several organizations and groups 
internationally, though no Canadian guidelines or consensus statement exists. 
Understanding the perspectives of key stakeholders is important in the successful 
implementation of any screening program. Patients’ interest in a universal tumor 
screening program and their need for and preferred form of consent has been 
largely unexplored, and there are no studies in the Canadian context.  
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1.13 Objective  
  This study is part of a larger project exploring the perspectives of key 
stakeholders including CRC patients, pathologists and genetic counselors regarding 
the benefits and barriers of universal tumor screening for LS.  
  The objective of this patient-oriented research project is to explore the perspective 
of CRC patients regarding universal tumor screening, especially their attitude, 
willingness to communicate with healthcare professionals and family members 
about test results, and their perspectives on the need for, and preferred mode of, 
informed consent.  
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CHAPTER 2  
 
 
 METHODS 
     
  This population-based survey was part of a larger project exploring the 
perspectives of key stakeholders regarding universal tumor screening. The initial 
phases of the study consisted of web-based national surveys of pathologists and 
genetic counselors. The present study encompasses a mail-out survey of patients 
with CRC in Newfoundland and Labrador, Canada. This cross-sectional survey 
was conducted with the objectives of understanding the patients’ attitudes towards 
universal tumor screening for Lynch Syndrome, the perceived benefits and barriers 
of screening and the need for (and preferred form of) informed consent. The data 
for this mail-out survey was collected and analysed entirely by the author of this 
thesis.  
 
2.1 Study Setting  
   This study was conducted at Memorial University of Newfoundland, Canada 
with the survey administered through the Dr. H. Bliss Murphy Cancer Centre in the 
Eastern Health Authority in St. John’s Newfoundland (NL). The period of the 
 44 
 
study was from January to December 2017. Ethics approval was obtained from the 
Newfoundland and Labrador Health research ethics Board (HREB), ref no: 
2016.277.   
 
2.2 Patient Oriented Research 
  
 Patient Oriented Research involves patients as research partners, rather than solely 
as study subjects (CIHR-strategy for patient-oriented research.2017). The current 
research was designed with patient engagement to meet several objectives: 1) to 
include a patient perspective in the overall design and conduct of the study; 2) to 
make the survey content and language more appropriate and understandable to the 
participants; 3) and to obtain a patient perspective on study conclusions and 
knowledge translation activities (e.g., an end-of-study patient workshop). The 
patient partner for the current study was identified for the larger project through 
personal networks of the study team. His lived experience was as a person who has 
had colon cancer and would be eligible to complete the survey. He was actively 
involved from the design and development of the survey, to the dissemination of 
results at the end of the study. The PI and her supervisor met regularly with the 
patient partner over the course of the study as decisions on content, language, 
administration, analysis and dissemination were made.   
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2.3 Sampling  
  The target population for this study was all living patients diagnosed with CRC in 
Newfoundland and Labrador over a three-year period preceding the survey 
administration (2017). This time frame was suggested by the Cancer Centre as 
having the most up-to-date data in the provincial cancer registry, the database used 
to recruit eligible respondents. As such, all living patients diagnosed with CRC 
from 2014 to 2016 were deemed eligible for the current study irrespective of age, 
gender and stage of tumor. The broad eligibility criteria were set to increase the 
sample size and to capture a wide range of responses. Eligible participants were 
identified from the Provincial Cancer Registry by Cancer Center staff within the 
patients’ circle of care. Mortality Clearance of these patients was obtained by the 
Cancer Centre from the Newfoundland and Labrador Center for Health 
Information (NLCHI) before survey mail-out.  
 
2.4 Survey Design and Development  
   The survey (see Appendix A) was developed by the PI to cover three broad 
areas: attitude, consent and communication regarding universal tumor screening. 
Specifically, we wanted to measure patients’ attitudes towards a provincial tumor 
screening program, their desire to take part, whether they saw the need for 
informed consent for such testing, and their willingness to talk with family 
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members about tumor testing results. With permission from the author, some 
questions were adapted from a survey conducted in the US examining patient 
perspectives on the benefits and barriers of universal screening (Hunter et al., 
2015). As the current literature is sparse on patient perspectives, this will allow 
some comparison of our findings with another patient population.  
    The survey consisted of 32 questions. The items were mostly close-ended 
questions with response options on Likert scales (strongly disagree-strongly agree), 
yes/no items, and items with multiple response options (e.g., besides you, who else 
in your family has had cancer?). A ‘not sure’ or ‘neither agree nor disagree’ option 
was included in most questions to account for a neutral response. One open-ended 
question was included to allow patients to describe any comments/suggestions they 
had about tumor screening.  
   The survey was divided into three sections; 1) Knowledge and understanding; 2) 
Attitude and opinions about screening, including the need for and preferred form of 
informed consent; and 3) Personal, demographic and family history information. 
Varying numbers and types of questions were included in each section.  
   In the first section, participants were asked about their prior knowledge about 
inherited forms of colon cancer and about universal tumor screening (items 1 and 
3). Participants were asked about their self-perceived risk of developing CRC 
based on family history (item 2). These questions were included to explore 
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knowledge about LS and universal screening among patients who have had colon 
cancer in NL, and to identify any association between risk perception and attitude 
towards the screening test.  
    The second section of the survey consisted of twenty-two items. Items 4 to 12 
were attitudinal items that explored participants’ attitudes towards having their 
tumor tested for LS. Components included perceptions of the benefits and risks of 
tumor testing (e.g., identifying high-risk families and worries about insurance, 
respectively). The responses were on 5-point Likert scales, with 1 being strongly 
disagree to 5 strongly agree. Some items were negatively worded to address the 
potential barriers of tumor testing. They included questions about financial barriers 
(e.g., “I would not take a tumor screening test it if I had to pay for it.”), social 
barriers (e.g., “I am concerned about any discrimination I could face based on the 
test result.”) and the way a tumor testing program might be offered (e.g., “People 
should not have their tumors screened if they don’t ask for the test.”). Another key 
item asked about the willingness of the participant to undergo the screening test 
(“If a tumor screening program for Lynch Syndrome were to be offered in 
Newfoundland and Labrador, how willing you might be to have your tumor 
screened?”). Items 14, 15, and 18 were designed to evaluate the self-perceived 
likelihood of communicating with family members and healthcare professionals 
(e.g., “Would you be willing to discuss your test result with any of your doctors or 
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other healthcare providers to guide your future care or treatment?” or “I would talk 
to my family members about the results of a tumor screening test done on my 
tumor.”). One question in this section asked the participants if they would need 
help from a healthcare professional to discuss the results of a screening test with 
their family members. This item was included to address the potential need for 
resource allocation if establishing a screening program was undertaken in the 
province (e.g., the need for meeting with genetic counselors or training primary 
care physicians or surgeons in facilitating communication with the family about 
tumor testing). Item 17, (“I understand the implications for my family members of 
a tumor screening test on my tumor.”) was developed to explore any associations 
among willingness to have one’s tumor screened, overall attitude, and 
understanding the implications the test has for family members of the participant.  
   The perspectives of patients regarding the need for, and preferred form of, 
informed consent for a screening program were probed in items 19, 20, and 23. 
Items 20 and 23 asked about the timing and type of consent if needed. In the last 
few items in the second section, participants were asked about their views on how 
a screening program could be run (e.g., when a health care professional should talk 
to the patients (item 22) or if and when educational materials should be provided 
(items 24 and 25)). Participants were asked who they thought should talk to the 
patients about screening tests in a multiple option question (item 21). The options 
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ranged from family doctor to genetic counselor, but an option to check “anyone 
above” was also included.   
    The third and final section of the survey consisted of demographic items (e.g., 
education level, marital status and number of children). Two items were included 
to learn about participants’ family history of cancer and colon cancer in particular. 
In case of a positive family history, participants were given the option to check the 
relationship with the affected family member (parent, children, spouse, sibling or 
others). This provided data to explore the relationships between positive family 
history and attitude towards screening tests and communication. The questionnaire 
concluded with the open-ended question asking for the participants’ comments and 
the option to participate in a prize draw (a $500 gift card).   
   Initial drafts of the survey cover letter and full survey were presented first to the 
patient partner who reviewed it for language, flow and level of respondent burden. 
Small revisions were made following his review and the survey was provided to 
the larger project team (consisting of an epidemiologist, gastroenterologist, and 
gynecological oncologist) for review. This interdisciplinary review process helped 
refine the questionnaire to best suit the study objectives, while minimizing medical 
jargon and respondent burden. The feedback from the patient partner was 
particularly beneficial in providing a critical patient perspective, resulting in 
rewording some items for better readability.      
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  Five demographic variables related to the eligible patients were extracted from 
the tumor registry by the Manager of the provincial cancer registry. They included 
date of birth, sex, date of diagnosis, stage of tumor at diagnosis and first three 
digits of postal code. The first three variables were extracted to obtain the age, sex, 
and year of diagnosis of the participants in order to explore if these were related to 
the survey responses. Staging of patients was based on The American Joint 
Committee on Cancer (AJCC) staging criteria, 7th edition (Edge & Compton, 
2010). This was extracted to examine associations and relationships among tumor 
stage and survey content areas. The first three digits of postal code was used to 
classify participants as urban or rural. The first character denotes the province 
(example: A for Newfoundland and Labrador). Second character which is 
numerical, denotes if the area is urban or rural. If the second character in the postal 
code was ‘0’, it was considered to be rural. If it was any other digit between one 
and nine it represented an urban area (Du Plessis & Statistics Canada, 2002). A 
data file containing the case ID of the eligible patients and the five variables were 
given to the research team by the Cancer Center. The file contained no patient 
names or other identifying information.  
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2.5 Survey Administration 
   A postal survey was chosen for several reasons, including: 1) a potential to reach 
a large sample size, making postal surveys more cost- and time-effective than 
telephone and personal interviews; 2) a large number of participants from rural 
areas and relatively older participants (often less likely to complete electronic or 
web-based surveys); and finally, 3) a postal survey is relatively easy to administer 
and allows respondents the freedom to complete at their convenience.  
   Eligible patients were assigned a case ID by the Cancer Centre starting from 
0001. This case ID was used henceforth for tracking the response and for linking 
the participant to clinical and demographic variables in the tumor registry needed 
for data collection and analysis. All participants were sent a survey packet to their 
mailing address given in the registry. Survey packets consisted of the survey 
booklet, an introduction letter from the cancer center containing the research 
team’s information, and a postage-paid return envelope addressed to the research 
team.  
   The survey booklets were also numbered serially from LS-0001 onwards to link 
back to the participant case ID and contained a cover letter followed by the 
questionnaire. The cover letter was signed by the research team and outlined the 
purpose of the study and provided instructions to complete the survey. It contained 
elements of consent, including the information that taking part in the study was 
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voluntary, respondents’ care would not be affected by survey participation, and 
withdrawal from the study could be accomplished by either mailing the unfilled 
survey back or by contacting the research team directly. Telephone numbers, email 
addresses and mailing addresses of the research team were provided for this 
purpose. A copy of the cover letter is provided in Appendix B.   
    The introduction letter from the Cancer Centre was addressed directly to the 
participant from the Manager of the Cancer Center. The letter outlined the purpose 
of the study, how the participant was selected and information about the 
researchers. The letter also informed respondents that the participation in the 
survey was voluntary and confidential. A copy of the introduction letter is given in 
Appendix C.    
   To preserve participant anonymity, the research team assembled the packets 
including the survey booklet and postage-paid return envelope without having the 
patients’ identifying information. They were inserted into custom-made mailing 
envelopes with same serial number as the survey. The prepared packets were 
provided to the Cancer Centre, who inserted the personalized introduction letter 
and addressed the outer envelopes according to the case ID and serial number on 
the envelope. The first survey mail-out was on May 29th, 2017.  
   A second mail-out was administered six weeks later to any participants who did 
not respond to the first mailing. Case IDs of undelivered surveys and that of 
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participants who declined participation by contacting the research team were 
removed from the reminder mail-out. The second round of mailing was 
administered in the same multi-step process as the first round and was mailed July 
20th, 2017.  
 
2.6 Strategies to increase response rate 
  Several measures recommended to increase response rate (Edwards, 2002) were 
taken as resources permitted. A monetary incentive was provided in the form of a 
prize draw. All participants were asked if they wanted their name to be included in 
prize draw at the end of the study. The winning respondent received a $500 gift 
card, mailed from the Manager of the Cancer Centre. The mailing envelope and the 
return envelope contained logos of both the Cancer Centre and Memorial 
University to emphasize institutional support of this research. The introduction 
letter from the cancer centre was addressed directly to the participant to establish a 
personal connection. A postage-paid, addressed return envelope was included in 
the packet for convenience. A follow-up was made in the form of a reminder mail 
out, also including the survey booklet and return envelope. The surveys themselves 
were printed in a large, reader-friendly font in the form of a booklet.  Additionally, 
the booklet was printed in pink colour as some research has shown an increase in 
survey response rates based on this colour (Etter, 2002).  
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2.7 Data Collection 
 
  The returned surveys arrived directly to the research team. The electronic data set 
containing the case ID and the five variables was merged with the survey data file. 
All data collection, storage and analysis were done using SPSS statistical software 
package, version 23.0 for windows (IBM, 2015). The information from the survey 
was manually entered into this electronic file by linking the case ID. The entered 
data were double-checked to ensure accuracy and to reduce errors. Separate 
variables were created for items with multiple response options to capture all 
information. For example, item 29 (Has anybody in your family ever had had 
cancer?) was followed by item 30 (If yes, mark x to all that apply). For item 30, 
separate variables were created for parent, children, spouse, sibling and others, and 
responses entered 1 or 0 for yes and no, respectively. This allowed the full capture 
of family cancer history. Any responses to the options “others, please specify” for 
items was entered separately. Depending on the responses, additional response 
categories were added to certain questions. For example, several respondents wrote 
in “at the time of diagnosis” for item 22. In that case a new category “at the time of 
diagnosis” was created to capture the information. Any comments and suggestions 
given by the respondent were entered to the data file verbatim. A second electronic 
file was kept for tracking the returned and unreturned case IDs. This was also 
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checked again at the end of the data collection to ensure accuracy. Finally, all 
surveys returned on or before August 31st, 2017 were included in the analysis.  
  Several steps were taken to ensure patient confidentiality, data privacy and 
security. De-identification of the participant list by assigning a random case ID was 
done by the Cancer Center to make the personal information confidential and not 
accessible to those outside the patients’ circle of care. No contact or identifiable 
personal information was entered to the electronic data file. Surveys were tracked 
only using the case ID. Returned surveys were handled directly by the research 
team. Survey booklets were stored in the office of the PI under lock and key. Data 
entry and analyses was completed using encrypted computers with password 
protection.  
 
2.8 Data Analysis  
 The collected information was double-checked for errors and discrepancies. An 
alpha level of 0.05 was considered significant. The data analysis was carried out in 
a series of steps as outlined below.  
 In the first step, survey response rates were determined, and responders and non-
responders were compared on available demographic information provided by the 
cancer registry. Responders and non-responders were compared using chi square 
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tests and independent t-tests as appropriate to look for any significant differences 
between them. 
   The second step consisted of the descriptive analysis of the responses. The 
descriptive statistics of all variables were examined. Frequency distribution was 
used for categorical variables while means and standard deviations were provided 
for continuous variables. The 5-point Likert type responses were considered as 
continuous for this purpose. The negatively worded questions (items 6, 7, 9,10 and 
11) were reverse coded to reflect higher scores for favourable/positive response 
towards universal tumor screening for LS. For several items, analysis was limited 
to descriptive statistics due to the nature of the study. To our knowledge, however, 
the current study represents the first survey ever conducted in the province about 
universal tumor screening. As such, simple descriptive analyses can provide 
valuable initial information for organizers of such a screening program. 
  In the next step, items measuring similar themes were pooled together to create 
scales. The internal consistency of the scales was measured using Chronbach’s 
alpha. The mean scores of the scales created were used for all further analyses. 
Several bivariate analyses were done to examine the associations between various 
survey items, attitude and communication scores, outcome variables and 
demographic variables using appropriate statistical tests. Willingness to undergo 
screening (item 13) and the participant’s thoughts on need for informed consent 
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(item 19) were considered as the outcome variables. The last step of data analyses 
was the multivariate analyses of outcome variables with other survey items and 
demographics. All variables with significant associations in the bivariate analyses 
were included in the regression model. Multivariate regression analyses explored 
the variables and its relationships to attitude, communication, willingness and 
consent protocol regarding universal screening of Lynch Syndrome. 
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CHAPTER 3  
 
RESULTS 
  Survey results are presented in two sections. The first section consists of 
descriptive statistics for the survey as whole and for each item. For several 
items, the analysis is limited to descriptive statistics because of the nature of 
the study. In the second section, scales are described, and several bivariate 
and multivariate analyses are presented that explore the associations among 
survey items, outcome variables and various clinical and demographic 
factors.  
 
3.1 Descriptive statistics  
  This section includes the response rates for the survey followed by the 
demographic characteristics of all eligible participants from the cancer 
registry. Survey respondents are compared with non-responders to assess if 
they are similar and representative of the eligible population. This is 
followed by the demographic and clinical characteristics of the responders 
(participants).  
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3.1.1 Response rates  
     
   There were 1155 patients diagnosed with CRC from 2014 to 2016 in the 
Provincial Cancer registry. Of these, 698 patients were eligible for the study 
after mortality clearance from the Newfoundland and Labrador Centre for 
Health Information (NLCHI). The survey packets were mailed to all 698 
eligible patients. Thirty were undeliverable and were returned to the cancer 
center, due to incorrect or incomplete mailing addresses. A number of 
eligible participants explicitly declined participation either by sending back 
unanswered surveys (n=19) or by informing the research team through 
telephone calls (n=8). We received 318 completed surveys, giving an 
effective response rate of 47.6% (318/668). The response flowchart is given 
in Figure 3.1. 
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Figure 3.1. Flowchart showing the survey participants and response 
rate.  
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  The demographic characteristics of the 698 patients are given in Table 3.1. 
The eligible patients were 56.6% male and 43.4% female. Their mean age 
was 70, ranging from 34-99 years. A little over half of the patients were 
residing in rural areas (52.4%) and 313 (45%) were diagnosed in 2016. 
Information on stage of tumor was not recorded in the cancer registry for 
315 (45.1%) of the patients.  
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Table 3.1. Characteristics of the eligible patients (N=698) 
Variable   Categories  N (%)  
Sex  
  
Male  395 (56.6%) 
Female  303 (43.4%) 
Age  
  
Mean age (SD)  70.5 (10.6) 
Range  34-99 
Year of Diagnosis  
  
  
2014 116 (16.6) 
2015 269 (38.5) 
2016 313 (44.8) 
Stage of Tumor a,b I 
IIA 
IIB 
IIC 
IIIA 
IIIB 
IIIC 
IVA 
IVB 
UNKc  
71 (10.2) 
122 (17.5) 
10 (1.4) 
9 (1.3) 
18 (2.6) 
101 (14.5) 
22 (3.2) 
21 (3.0) 
8 (1.1) 
1 (0.1) 
 Area Rural 
  
366 (52.4) 
  Urban  332 (47.6) 
SD: Standard Deviation 
a information regarding the stage of tumor was missing for 315 eligible participants.  
b the stage of tumor is based on American Joint committee on cancer 7th edition (Edge & 
Compton, 2010) 
c UNK- Unknown 
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   Survey responders and non-responders were compared to explore any 
differences among available demographic and clinical variables (Table 3.2).  No 
significant differences were observed in sex, area of residence, year of diagnosis 
and stage of tumor between the two groups. Patients who responded to the survey 
were younger than patients who did not, as determined by independent sample t-
test (Mean difference =- 2.51; t (694.7) = -3.15; p<0.05). 
 
Table 3.2. Comparison of responders and non-responders of the survey.  
Variable  Responders Non-responders  Test  
Age  Mean = 69.1 Mean = 71.6 Mean difference =-
2.51  
(t=-3.15; p<0.05) 
Sex Females 44.3% Females 42.6% Chi square 0.206;  
p -.650 
Area of 
residence  
Rural 52.8% Rural 52.1% Chi square .036;  
p- .849 
Year of 
diagnosis 
2014- 17.6% 2014- 15.7% Chi square .0448;  
p- .799 
Stage of 
tumor* 
Stage I – 
10.3% 
Stage I – 10% Chi square 7.036;  
p- .722 
*Stage of tumor information missing for 45.1% individuals. 7 cells (31.8%) have 
expected counts less than 5; Chi square test not valid.  
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   The demographic characteristics of the responders are given in Table 3.3. The 
mean age of the responders was 69, (SD = 9.7; range 43-94); 55.7% were male.  
Among the participants, 168 (52.8%) were living in rural areas and 150 (47.2%) 
in urban areas. The highest level of education for 51% of respondents was a high 
school certificate or lower, whereas only 18 (5.7%) participants had reported an 
education level higher than a bachelor’s degree. Most of the participants were 
married or living with a partner (71%) and had children (mean number of children 
2; SD 1.6, range 0-10). 
  The clinical characteristics and family history information of the responders are 
given in Table 3.4. Among them, 44.7% (n=142) were diagnosed in 2016. 
Information on stage of tumor was not recorded in the cancer registry for 141 
(44.3%) of the patients.  
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Table 3.3. Demographic Characteristics of the participants (N= 318) 
Variable  Categories  N (%) 
Sex  Male  
Female 
177 (55.7) 
141 (44.3) 
Age  Mean age (SD)  
Range 
69 (9.7) 
43- 94  
Area of residence Rural  
Urban 
168 (52.8) 
150 (47.2) 
Highest level of 
Education a 
 
 
 
High School certificate or 
lower  
Trade school/non-university or 
some university  
Bachelor’s degree or higher  
 
162 (50.9) 
119 (37.4) 
 
28(8.8) 
Current marital 
status b 
 
 
Single 
Married or living with a 
partner 
Divorced/separated 
Widowed 
  
18 (5.7) 
227 (71.4) 
19 (6.0) 
46 (14.5) 
Number of children c 
 
 
None 
1-3 
3-5 
>5  
  
18 (5.7) 
218(68.6) 
55 (17.3) 
17 (5.3) 
  
a Information regarding the highest level of education was missing for 9 participants.  
b Information regarding the marital status was missing for 8 participants.  
c Information regarding the number of children was missing for 10 participants 
SD: Standard Deviation 
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Table 3.4. Clinical characteristics and family history of the participants 
(N=318) 
Variable  Categories  N (%) 
Year of Diagnosis  2014 56 (17.6) 
2015 120 (37.7) 
2016 142 (44.7) 
Stage of Tumor a,b  
  
I 33 (10.4) 
IIA 50 (15.7) 
IIB 4 (1.3) 
IIC 4 (1.3) 
IIIA 9 (2.8) 
IIIB 51 (16.0) 
IIIC 11 (3.5) 
IVA 13 (4.1) 
IVB 2 (0.6) 
Family History of 
Cancer (self-
reported) 
 
Yes 267 (85.9%) Parent 134 (42.1) 
Children 25 (8.1) 
Spouse  47 (15.2) 
Sibling 139 (45.0) 
Others  93 (30.0) 
No 44 (14.1%)   
Family History of 
colon cancer (self-
reported) 
 
Yes 137 (44.3%) Parent 43 (13.9) 
Children 9 (2.9) 
Spouse  12 (3.9) 
Sibling 55 (17.8) 
Others 57 (18.4) 
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3.2 Descriptive statistics of survey items 
  This section details the descriptive statistics of the participants’ responses 
to the survey items. The section is organized based on the objective of the 
questions in the survey. Most participants completed the entire survey, but 
some surveys were missing data, ranging from 0 to 3.8% of items. Some 
participants left groups of questions unanswered. It is plausible that pages 
might have been stuck together while turning sheets in those cases. 
Descriptive statistics of each subsection are described in the following 
sections.  
 
3.2.1 Knowledge  
  Participants had generally little knowledge about inherited forms of colon 
cancer and universal tumor screening. Around 30% of the participants had 
never heard about inherited forms of colon cancer, whereas only 9% had 
heard a fair amount or more. While most of the participants (83.1%) had 
No 172 (55.7%)   
a based on American Joint Committee on Cancer (AJCC) guidelines, 7th Edition (Edge 
& Compton, 2010).  
b. Information on stage of tumor is missing for 44.3% of the participants.  
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never heard of universal tumor screening for Lynch Syndrome prior to this 
survey, only four participants (1.25%) had heard a fair amount or more.  
Many participants did not agree with the statement “I have always suspected 
I would get cancer, because it runs in my family” (221/318; 69.5%). Table 
3.5 shows the descriptive statistics of items related to knowledge and risk 
perception.  
  
  
69 
Table 3.5. Survey Responses regarding Knowledge and risk perception 
Question Mean 
response  
SD Missing 
(%)  
Response values frequency (%)  
1 least positive, 5 most positive 
1 2 3 4 5 
Before today, how much had 
you heard about genetic or 
inherited forms of colon 
cancer? 
2.09 0.971 5  
(1.6) 
92 
(29.4) 
135 
(43.1) 
58  
(18.5) 
21 
(6.7) 
7 
(2.2) 
 I have always suspected I 
would get cancer, because it 
runs in my family. 
2.72 1.195 6  
(1.9) 
60 
(19.2) 
77 
(24.2) 
84  
(26.9) 
71 
(22.8) 
20 
(6.4) 
Before today, how much had 
you heard about ‘Universal 
tumor screening for Lynch 
Syndrome’? 
1.23 0.593 6  
(1.9) 
261 
(83.7) 
35 
(11.2) 
12  
(3.8) 
3  
(0.9) 
1  
(0.3) 
SD: Standard Deviation 
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3.2.2 Attitude towards universal screening  
  Attitude towards universal screening among participants was clearly 
positive. The majority (259; 81.4%) of participants indicated they would be 
willing to have their tumor screened if a screening program were offered in 
NL. Among the participants, 89% agreed that universal tumor screening 
would be useful for high risk individuals, and 87% believed their family 
could benefit from this test. Most of the participants agreed that the result of 
a tumor screening test would help them plan their future (77%) and felt that 
the test should be available for anyone who has had colon cancer and wishes 
to have information about his/her inherited risk (92%). Only 27 % of the 
participants said they would not take a tumor test if they had to pay for it, 
and 37% were worried that the testing would affect their ability to get health 
or life insurance in the future. A small portion of the participants agreed to 
the statement that people should not have their tumors screened if they didn’t 
ask for it (18%), whereas 10% of the participants did not want to know any 
genetic risks they might have. Twenty one percent of them were concerned 
about any discrimination they could face based on the test result. These 
results are summarized in Table 3.6.    
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Table 3.6: Descriptive frequencies of survey responses about attitude towards universal screening.  
Item  Mean 
response 
SD Missin
g 
(%) 
Response values frequency (%) 
1 least positive, 5 most positive 
1 2 3 4 5 
Universal tumor screening of colon 
cancer tumors would be useful for 
identifying high risk individuals.  
4.3 0.78
2 
7  
(2.2) 
6 
(1.9) 
2 
(0.6) 
20 
(6.4) 
147 
(47.3) 
136 
(43.7) 
My family could benefit from this 
test.   
4.29 0.79
5 
5  
(1.6) 
4 
(1.3) 
5 
(1.6) 
27 
(8.6) 
136 
(43.5) 
141 
(45.0) 
I would not take a tumor screening 
test it if I had to pay for it. *  
3.25 1.26 10 (3.1) 35 
(11.4) 
51 
(16.6) 
84 
(27.3) 
79 
(25.6) 
59 
(18.6) 
People should not have their 
tumors screened if they don’t ask 
for the test.*  
3.72 1.14
9 
9  
(2.8) 
13 
(4.2) 
45 
(14.6) 
47 
(15.2) 
116 
(37.5) 
88 
(28.5) 
The result of a tumor screening test 
could help me plan my future.  
3.96 0.88
8 
9  
(2.8) 
8 
 (2.6) 
11 
(3.6) 
46 
(14.9) 
163 
(52.8) 
81 
(26.2) 
I would be worried that universal 
tumor screening would affect my 
ability to get health or life 
insurance in the future. *   
2.93 1.11 11 
(3.5) 
29  
(9.4) 
88 
(28.7) 
92 
(30.0) 
71 
(23.1) 
27 
(8.8) 
I am concerned about any 
discrimination I could face based 
on the test result. *  
3.5 1.1 11 
(3.5) 
12 
(3.9) 
57 
(18.6) 
60 
(19.5) 
123 
(40.1) 
55 
(17.9) 
I do not want to know about any 
genetic risks I might have. *  
3.98 1.02 7  
(2.2) 
11 
(3.5) 
22 
(7.1) 
33 
(10.6) 
140 
(45.0) 
105 
(33.8) 
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The test should be available to 
anyone who has had colon cancer 
and wishes to have information 
about his/her risk of inherited 
forms of colon cancer.   
4.36 0.80
6 
5 
(1.6) 
6 
(1.9) 
7 
(2.2) 
8  
(2.6) 
138 
(44.1) 
154 
(49.2) 
If a tumor screening program for 
Lynch Syndrome were to be 
offered in Newfoundland and 
Labrador, how willing you might 
be to have your tumor screened?  
4.24 0.78
9 
6  
(1.9) 
1  
(0.3) 
5 
(1.6) 
47 
(15.1) 
123 
(39.4) 
136 
(43.6) 
SD: Standard Deviation 
* : These items were reversely coded to reflect a positive attitude towards universal screening 
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3.2.3 Communication with health care professionals and family 
members  
  Overall, participants were positive about communicating their results with 
healthcare professionals and family members. Nearly all were willing to 
discuss their test result with doctors and other healthcare professionals to 
guide future treatment (n=299; 94%). When asked if they would need help 
from a healthcare professional to discuss the results with their family, 195 
patients (61.3%) agreed that they would. A vast majority of the participants 
(n=300; 94.3%) indicated they would talk to their family members about the 
test results. Among the participants, 242 (76.2%) said they understood the 
implications a screening test could have on their family and most of them 
(288; 90.5%) agreed that they would encourage their family members to 
learn more about the implications as well. The descriptive frequencies are 
given in Table 3.7. 
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Table 3.7: Descriptive frequencies of survey responses about communication.  
Question Mean 
response 
SD Missing 
(%) 
Response values frequency (%) 
1 least positive, 5 most positive 
1 2 3 4 5 
Would you be willing to discuss your test 
result with any of your doctors or other 
health care providers to guide your future 
care or treatment?  
 
4.41 .582 6  
(1.9) 
0 1 
(0.3) 
12 
(3.8) 
157 
(50.3) 
142 
(45.5) 
I would talk to my family members about 
the results of a tumor screening test done 
on my tumor. 
 
4.4 .576 6 
(1.9) 
0 1  
(0.3) 
11 
(3.5) 
161 
(51.6) 
139  
(43.7) 
I would need help from a healthcare 
professional to discuss the results of a 
screening test with my family members. 
3.55 1.053 8  
(2.5) 
10 
(3.2) 
53 
(17.1) 
52 
(16.8) 
145  
(46.8) 
50 
(16.1)  
I understand the implications for my 
family members of a tumor screening test 
on my tumor. 
 
3.88 .763 10 
(3.1)  
4 
(1.3) 
12 
(3.9) 
50 
(16.2)  
193 
(62.7) 
49 
(15.9) 
I would encourage my family members to 
learn more about the implications of a 
tumor screening test done on my tumor. 
 
4.21 .706 8 
(2.5)  
5 
(1.6) 
2  
(0.6) 
15 
(4.8) 
188  
(60.6) 
100 
(32.3)  
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Would you be willing to discuss your test 
result with any of your doctors or other 
health care providers to guide your future 
care or treatment?  
 
4.41 .582 6  
(1.9) 
0 1  
(0.3) 
12 
(3.8) 
157 
(50.3) 
142 
(45.5) 
I would talk to my family members about 
the results of a tumor screening test done 
on my tumor. 
 
4.4 .576 6  
(1.9) 
0 1  
(0.3) 
11 
(3.5) 
161 
(51.6) 
139  
(43.7) 
I would need help from a healthcare 
professional to discuss the results of a 
screening test with my family members. 
3.55 1.053 8  
(2.5) 
10  
(3.2) 
53 
(17.1) 
52 
(16.8) 
145 
(46.8) 
50  
(16.1)  
SD: Standard Deviation 
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3.2.4 Need for and form of informed consent  
  Participants’ perspectives regarding the need for, and preferred form of, 
informed consent were more variable than their attitudes towards tumor 
testing. While a large number (62.6%) were in favour of consent being 
obtained for universal tumor screening, a quarter of the respondents did not 
think consent was necessary. Ten percent of the participants were unsure 
about the need for consent. Most of the participants (63%) thought that the 
consent can be taken at the same time as the surgical consent, but 20% were 
not sure about the timing. More than half of the participants preferred a 
written consent (51.6%), whereas 21 patients (6.77) indicated they wanted 
both verbal and written consent. Eleven percent of the responders were 
unsure about the type of consent. The distribution of responses for the items 
related to need and form of consent is given in Figure 3.2.  
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Figure 3.2. Pie charts showing the distribution of responses for items related to consent.  
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3.2.5 Informing and educating patients  
  When asked about who should talk to patients about universal screening 
(item 21), participants wanted to be informed, but they expressed no clear 
preference for which healthcare professional should be responsible for these 
discussions. The preferences ranged from genetic counselor (19.5%), 
oncologist (34.3%), family doctor (40.3%), surgeon (45.3%), or any one of 
these professionals (52.5%). A bar graph showing this distribution is given 
in Figure 3.3. 
 
Figure 3.3. Bar chart showing the distribution of responses to item 21.  
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  Most of the study participants (59.1%) were of the opinion that patients 
should be informed about tumor testing when they first receive the diagnosis. 
Almost all participants (91.5%) agreed that they needed written educational 
materials about universal screening and the risk of inherited colon cancer. 
While over half of them said the educational materials should be provided 
before the day of surgery, open comments on the survey revealed a small 
minority who preferred materials at the time of diagnosis. One participant 
noted they “would like to see more educational material displayed -maybe in 
Dr’s waiting room”. Participants’ responses on items related to informing 
and educating patients are given in Figure 3.4. 
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Figure 3.4. Pie charts showing the distribution of survey responses related to informing and educating patients.
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3.2.6 Comments and suggestions  
  An open-ended question was given at the end of the survey questionnaire 
for the participants to leave any comments or suggestions about tumor 
testing. Sixty-one people provided comments, which were positive. The 
following comments were typical: 
• “Very happy to hear about it. Should be done in my opinion.” 
• “I hope that this screening testing will be available soon for my 
children and grandchildren.” 
• “I feel this testing is very important for myself and my family. I 
have two grown sons and siblings that may benefit from this 
testing.” 
• “I think this is important, a screening would obviously be pre-
emptive for the next generation's ability to seek timely testing such 
as colonoscopy, etc.” 
• “I do feel some cancers are hereditary, so if this can help my family 
or other patients, go for it.” 
• “This testing should be standard procedure. My question is why is 
it not?” 
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  One participant indicated he/she was, “very concerned about insurance 
implications; my medical info should remain confidential.” Overall however, 
participants were very supportive of tumor testing and thought it would be 
beneficial to themselves and their family. 
 
3.2.7 Section Summary 
  The descriptive statistics indicated that participants are willing to undergo 
screening, have a favourable attitude towards it, and are willing to 
communicate about the test results with their families and healthcare 
professionals. Patients also think they should be informed about the test at 
the earliest occasion and require educational materials about universal 
screening. The majority of participants prefer a written consent for universal 
screening for LS, taken at the same time as surgical consent.   
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3.3 Inferential analyses  
  This section presents inferential statistics performed on survey data. First, 
the creation of scales from survey items is described. Secondly, several 
bivariate and multivariate analyses are presented that explore the 
associations and relationships between two or more variables.  
  
3.3.1 Creation of scales  
  Several items in the survey measured the attitude of the participants 
towards universal screening for Lynch Syndrome. These nine items were 
summed, and the average taken to create an attitude scale named ATT. The 
internal consistency of the scale was adequate (Chronbach’s α- 0.631). The 
mean score of the scale was 3.8 (SD=0.5), showing a positive attitude 
towards screening by the participants.   
  Similarly, items from the questionnaire pertaining to communication were 
summed and the average taken to create the communication scale (COMM). 
When items 14, 15, 16 and 18 were included in the internal consistency 
analysis, the scale had a low Chronbach’s alpha of 0.525.  
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Further examination revealed that item 16 had a low item-total correlation 
(0.144) and was removed. Thus, the final COMM scale was created with 
three items, namely 14, 15 and 18, with a good internal consistency 
(Chronbach’s α -.703). The mean score of COMM scale was 4.34 (SD 0.49). 
Item 16 was included as a separate item in the subsequent analyses. High 
scores on COMM scale indicate more communication with family members 
and healthcare professionals. Table 3.8 shows the properties of both ATT 
and COMM scales.  
Table 3.8 Properties of ATT and COMM scales.  
Scale  Items 
included  
Mean score 
(S.D) 
Range  Chronbach’s 
α 
ATT 4, 5, 8, 12 
6*, 7*, 9*, 
10*, 11* 
3.8 (0.5) 2.56 - 5.0 0.631 
COMM  14, 15, 18  4.34 (0.49) 2.33 – 5.0  0.703 
ATT: Attitude scale  
COMM: Communication scale 
*These items were reversely coded to reflect a positive attitude towards universal 
screening. 
SD: Standard Deviation 
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3.3.2 Bivariate and multivariate analyses  
  The section begins with a correlational analysis of key survey items. First, 
the scales (ATT and COMM) were correlated with each other, with other 
survey items and with demographic variables. Second, the associations of the 
two outcome variables (willingness and consent) with other survey items, 
demographic variables and the scales were explored using the appropriate 
statistical tests. 
 
3.3.2.  Analysis of the scales (ATT and COMM)  
  A positive correlation was observed between attitude (ATT) and the 
communication (COMM) scales, indicating that the more positive attitude 
participants have towards universal screening, the more likely they are to 
communicate with healthcare providers and family members (r=0.492; 
p<0.01). Higher scores on the ATT and COMM scales were positively 
correlated with an increased willingness to undergo screening. However, the 
need for informed consent was not significantly correlated with either 
attitude towards tumor testing or willingness to communicate about it. Prior 
knowledge about inherited forms of colon cancer and universal screening 
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was associated with a higher score on COMM (p<0.05), but not on ATT. 
Participants with higher levels of knowledge were more likely to indicate 
willingness to communicate with family and healthcare professionals about 
tumor testing. Participants with a higher risk perception had a less positive 
attitude towards screening test (r= -.141; p<0.05), but no correlation was 
observed with the COMM scale (r=0.006, p-NS). The correlation matrix of 
ATT and COMM with the other survey items is given in Table 3.9. 
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Table 3.9. Correlational analyses of ATT, COMM scales with other survey items.  
 ATT a 
COM
M b 
Willing
ness. 
Need 
for 
consent 
Prior 
knowledge 
about 
inherited 
colon cancers 
Prior 
knowledg
e about 
universal 
screening
. 
Cancer 
risk 
perception 
Understandin
g 
implications 
for family. 
Need 
for 
help 
from 
HCP 
c 
ATT a 1         
COMM b 
.492*
* 
1        
Willingnes
s 
.381*
* 
.581** 1       
Need for 
consent. 
-.024 .045 .051 1      
Prior 
knowledge 
about 
inherited 
colon 
cancers 
.056 .153** .105 .001 1  .   
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Prior 
knowledge 
about 
universal 
screening. 
.032 .119* .055 .057 .419** 1    
Cancer 
risk 
perception. 
-.141* .006 -.011 -.004 .205** .181** 1   
Understan
ding 
implicatio
ns for 
family. 
.199 .352 .235 .030 .119 -.035 .009 1  
Need for 
help from 
HCP c. 
-.031 .144 .057 .109 -.018 -.003 .154 .119 1 
a Attitude scale  
b Communication scale  
c Healthcare professional  
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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 Bivariate analyses of ATT and COMM with demographic and clinical 
variables were conducted separately to explore any significant associations. 
Age was negatively correlated with both ATT and COMM. Younger 
participants were observed to have a higher score in the attitude scale (r=-
.117; p<0.01), as well as in the communication scale (r=-.134; p<0.01). Thus, 
younger participants had more positive attitudes towards tumor testing and 
were more likely to communicate with family members and healthcare 
professionals about it. Independent sample t tests were conducted to compare 
the ATT and COMM scores across dichotomous variables such as sex, place 
of residence, family history of cancer, and family history of colon cancer. 
Among these, participants residing in urban areas (Mean= 4.43, SD= .480) 
were found to have higher COMM scores than those from rural areas (Mean= 
4.26, SD= .497). This difference was statistically significant; t (307) = 2.93, 
p=.004. One-way ANOVA tests showed that COMM scores were different 
across the levels of education of the participants. Participants with higher 
levels of education were found to score higher in COMM score, showing 
greater intentions to communicate their test results, F (2,302) =9.68, p<0.01. 
However, no difference was observed in the ATT scores across place of 
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residence or level of education. Family histories of cancer in general or colon 
cancer in particular were not associated with attitude or communication 
scores. The results of bivariate analyses of ATT and COMM with 
demographic and clinical variables are given in Table 3.10 and Table 3.11 
respectively.  
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Table 3.10. Bivariate analyses of ATT with demographic and clinical 
variables.  
Variable 
 
ATT 
  Mean 
(SD) 
Test statistic (df) Sig 
Age   r=-.117* 
 
.046 
Sex Male 
3.80 
(.510) 
t (291) =.946  .345 
Female 3.85 
(.502) 
Area of 
residence      
                
Rural 3.821 
(.476) 
t (291) = .177  
.860 
Urban 3.832 
(.539) 
Family 
history of 
Cancer 
No 3.785 
(.567) 
t (289) = .585 .559 
Yes 3.836 
(.497) 
Family 
history of 
colon cancer                    
No 3.855 
(.539) 
t (287) =.864 .389 
Yes 3.803 
(.464) 
Level of 
education 
Highschool 
certificate or lower 
3.79 
(.503) 
F (2, 287) = 1.342 .263 
Trade school/some 
university 
3.84 
(.526) 
Bachelor’s degree 
or higher 
3.96 
(.438) 
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Marital status Single 3.77 
(.599) 
F (3,286) = 1.149 .330 
Divorced/separated  3.96 
(.505) 
Widowed 3.72 
(.545) 
Married/Living 
with a partner  
3.83 
(.485) 
Number of 
children 
  r=.013 .825 
Year of 
diagnosis 
  r= -.030 .609 
Stage of 
tumor a 
I  3.90 
(.486) 
 
 F (8,154) = .479 .870 
IIA 3.78 
(.503) 
IIB 3.77 
(.192) 
IIC 3.61 
(.584) 
IIIA 3.89 
(.319) 
IIIB 3.76 
(.448) 
IIIC 3.80 
(.538) 
IVA 3.82 
(.493) 
IV B 4.22 (00) 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
SD: Standard Deviation  
df: Degrees of freedom 
a Information on stage of tumor was missing for 141 (44.3%) patients. 
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Table 3.11. Bivariate analyses of COMM with demographic and clinical 
variables. 
Variable 
 
ATT 
  Mean 
(SD) 
Test statistic (df) Sig 
Age   r=-.134* .018 
Sex Male 
4.321 
(.469) 
t (307) =.851 .396 
Female 4.370 
(.526) 
Area of 
residence      
                
Rural 4.266 
(.497) 
t (307) =2.93 .004 
Urban 4.429 
(.480) 
Family 
history of 
Cancer 
No 4.21 
(.453) 
t (304) =1.788 .075 
Yes 4.362  
(.50) 
Family 
history of 
colon cancer                    
No 4.303 
(.510) 
t (302) =1.881 .061 
Yes 4.410 
(.464) 
Level of 
education 
Highschool 
certificate or lower 
4.23 
(.483) 
F (2,302) = 9.68** .000 
Trade school/some 
university 
4.44 
(.493) 
Bachelor’s degree 
or higher 
4.55  
(.435) 
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Marital status Single 4.333 
(.5480 
F (3,301) =1.745 .158 
Divorced/separated  4.574 
(.468) 
Widowed 4.260 
(.557) 
Married/Living 
with a partner  
4.33 
(.477) 
Number of 
children 
  r=-.026 .648 
Year of 
diagnosis 
  r=-.022 .699 
Stage of 
tumor a 
I  4.40 
(.470)  
 F (8, 162) = 1.369 .214 
IIA 4.35 
(.511) 
IIB 4.89 
(.192) 
IIC 4.50 
(.430) 
IIIA 4.37 
(.611) 
IIIB 4.32 
(.424) 
IIIC 4.27 
(.327) 
IVA 4.10 
(.550) 
IV B 4.833 
(.235) 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
SD: Standard Deviation  
df: Degrees of freedom 
a Information on stage of tumor was missing for 141 (44.3%) patients. 
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Prior knowledge about inherited colon cancer or universal screening was not 
correlated with any clinical or demographic variables, whereas people with a 
positive family history of colon cancer were more likely to know about 
inherited forms of colon cancer (p<0.05). This risk perception was 
significantly correlated with their knowledge about inherited colon cancer and 
universal screening (p<0.01).  
 
3.3.3. Willingness to undergo screening.  
  The outcome variable willingness describes the participants’ willingness to 
undergo a universal tumor screening test if it were offered in our province. 
Bivariate analysis of willingness with other variables including the ATT and 
COMM scales, other survey items, and clinico-demographic variables was 
done. As mentioned earlier, ATT and COMM scores were positively 
correlated with willingness. Higher scores on the ATT scale were associated 
with a greater willingness to undergo screening (r=0.381, p<0.01). Similarly, a 
high score on the COMM scale was associated with increased willingness to 
undergo screening (r=0.581, p<0.01). Patients’ willingness to get their tumor 
tested for LS was not related to their prior knowledge about inherited forms of 
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colon cancer and universal screening. Likewise, their cancer risk perception 
was not found to influence willingness to participate in the screening program. 
Patients’ agreement with the statement “I understand the implications of a 
tumor screening test on my family,” was positively correlated with their 
willingness to undergo screening (r=0.235, p<0.01). The results of the 
correlation of willingness with scales as well as survey items are given in 
Table 3.12.  
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Table 3.12. Correlational analyses of willingness with the ATT, COMM scores and other survey items. 
 Willing
ness. 
ATT a COM
M b 
Prior 
knowledge 
about 
inherited 
colon 
cancers 
Prior 
knowledg
e about 
universal 
screening. 
Cancer 
risk 
perception
. 
Understanding 
implications 
for family. 
Need for 
help from 
HCP c. 
Willingness. 1        
ATT a .381** 1       
COMM b .581** .492** 1      
Prior 
knowledge 
about 
inherited 
colon cancers 
.105 .056 .153** 1     
Prior 
knowledge 
about 
universal 
screening. 
.055 .032 .119* .419** 1    
Cancer risk 
perception. 
-.011 -.141* .006 .205** .181** 1   
Understandin
g implications 
for family. 
.235 .199 .352 .119 -.035 .009 1  
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Need for help 
from HCP c. 
.057 -.031 .144 -.018 -.003 .154 .119 1 
 a Attitude scale  
b Communication scale  
c Healthcare professional  
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
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  The outcome ‘willingness’ was examined for any correlations with clinical and 
demographic variables. Age was found to be negatively correlated with 
willingness. Younger people were more willing to undergo universal screening (r 
=-.215; p<0.01). The willingness to undergo tumor screening was different 
between participants who reported a positive family history of colon cancer and 
others, t (305) = 2.92; p<0.01. A significant weak correlation between number of 
children and willingness was also observed (r=-.137, p<0.05). No significant 
differences in willingness to undergo tumor screening was observed across 
variables like sex, place of residence, level of education and marital status of the 
participant. The results of bivariate analysis of willingness with clinical and 
demographic variables are given in Table 3.13.  
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Table 3.13. Bivariate analyses of willingness with clinical and demographic 
variables.  
Variable  Willingness  
  Mean (SD) Test statistic (df) Sig 
Age   r=-.117* 
 
.046 
Sex 
Male 
4.20 (.816) t (310) =.1.104 .271 
Female 
 
4.30 (.751) 
Area of 
residence      
                
Rural 4.20 (.782) t (310) = 1.143   .254 
Urban 4.30 (.795) 
Family 
history of 
Cancer 
No 4.05 (.861) t (307) = 1.866 .063 
Yes 4.28 (.768) 
Family 
history of 
colon cancer                    
No 4.14 (.840) t (305) = 2.92** .004  
Yes  4.40 (.682) 
Level of 
education 
Highschool 
certificate or 
lower 
4.17 (.752)  F (2, 304) = 
2.381 
.094 
Trade 
school/some 
university 
4.38 (.751) 
Bachelor’s degree 
or higher 
4.29 (.937) 
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Marital status Single 4.17 (.707) F (3,304) = 2.253 .082 
Divorced/separate
d  
4.53 (.772) 
Widowed 4.02 (.856) 
Married/Living 
with a partner  
4.28 (.770) 
Number of 
children 
  r=-.137* 
 
.017 
Year of 
diagnosis 
  r=.089 
 
.115 
Stage of 
tumor a 
I  4.16 (.884) 
 
 F (8,165) = 
1.867  
.068 
IIA 4.26 (.777) 
IIB 5.0 (.00) 
IIC 4.00 (.816) 
IIIA 4.67 (.50) 
IIIB 4.20 (.782) 
IIIC 3.82 (.874) 
IVA 3.77 (.927) 
IV B 5.00 (.00) 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
SD; Standard Deviation  
df: Degrees of freedom 
a Information on stage of tumor was missing for 141 (44.3%) patients. 
 
 
 102 
 
  Variables found to be significantly associated with participants’ willingness to 
undergo universal screening in the bivariate analyses, namely age, family history 
of colon cancer, number of children, understanding of implications, and the two 
scales measuring patients’ attitude and communication were included in the 
multivariate analysis. A multivariate regression model was developed using 
Generalized Linear Models, adding and removing variables using the mixed 
selection method. There was homoscedasticity and no evidence of 
multicollinearity. The assumption of normality was met, as assessed by a Q-Q plot. 
The final regression model included age, ATT score, COMM score and family 
history of CRC with all four variables added significantly to the model (p<0.05). 
Age was weakly, albeit significantly associated with willingness to undergo 
screening (OR-0.992, 0.98-0.999). A higher score on the ATT scale was associated 
with an increased willingness to undergo screening (OR- 1.21. 1.02-1.43). The 
more likely patients are to communicate with healthcare professionals and family 
members, the more willing they are to have their tumors screened (OR- 2.14, 1.8-
2.5). A positive family history of CRC, however, slightly lowers their inclination 
to get screened for LS, when age, attitude and communication are considered (OR-
0.858, 0.74-0.93). The parameter estimates of the final regression model are given 
in Table 3.14.  
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Table 3.14. Willingness to undergo screening by age, ATT score, COMM 
score and family history of CRC. 
 
Variable 
Sig.  OR      95% CI 
Lower  Upper  
Intercept  .069 2.38 .935 6.086 
COMM .000 2.14 1.805 2.553 
ATT .022 1.21 1.028 1.438 
[Family history of colon 
cancer=0] 
.041 .858 .740 .994 
[Family history of colon 
cancer=1] 
. 1 . . 
Age .027 .992 .984 .999 
 
 
3.3.4 Need for consent  
 
  Item 19, need for consent before universal screening, was considered as an 
outcome variable and was tested for associations with the ATT and COMM scales, 
as well as other survey items, willingness to undergo tumor screening and clinico-
demographic variables. The outcome was binomial, grouping participants who 
answered yes to ‘1’ and those who answered no or unsure to ‘0’. Categorical and 
continuous variables were included in the bivariate analysis using Chi square tests 
and students t test as appropriate. 
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  The need for consent was not associated with participants’ attitude or 
communication scores, as evidenced by non-significant test results with the ATT 
and COMM scales. The need for consent was not associated with the willingness 
of the participant to undergo screening or their understanding of the implications of 
the tumor screening test on their family members. Neither prior knowledge about 
tumor testing, nor risk perception, were associated with opinions about consent. 
The results of correlational analyses of the need for consent with the scales, 
willingness and other survey items are given in Table 3.15.  
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Table 3.15. Bivariate analyses of need for consent with ATT, COMM scales, 
willingness and other survey items.  
 
 
Variable  
 
 Consent  
(1=yes) 
 
Consent 
(0=others)  
 
Mean SD Mean SD t df Sig. 
Willingness. 4.27 0.765 4.19 0.837 -.890 307 .374 
ATT 3.82 0.45 3.84 0.538 .402 289 .688 
COMM 4.364 0.481 4.318 0.514 -.780 305 .436 
Prior knowledge 
about inherited 
colon cancers 
2.098 1.007 2.098 0.910 -.024 308 .981 
Prior knowledge 
about universal 
screening. 
1.257 0.652 
 
1.187 0.475 
 
-.997 308 .320 
Cancer risk 
perception. 
2.730 1.192 2.741 1.198 .071 307 .943 
Understanding 
implications for 
family. 
3.903 0.788 3.855 0.698 
 
-.525 305 .600 
Need for help from 
healthcare 
professional to 
communicate with 
family 
3.64 1.038 3.41 
 
1.064 -1.924 306 .055 
SD: Standard Deviation  
df: Degrees of freedom 
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Among the clinical and demographic variables, place of residence and level of 
education of the participants were associated with a difference in consent outcome. 
People living in urban areas were more likely to think a separate consent was 
required for tumor testing (Chi square = 5. 86; p<0.05). Similarly, patients with 
higher education were more likely to require consent (Chi square = 10.5: p<0.01).  
Age, sex and family history of colon cancer were not significantly associated with 
patients’ need for consent. No other clinical and demographic variables were 
significantly associated with the consent outcome. The results of the bivariate 
analyses exploring need for consent and various clinical and demographic 
outcomes are given in Table 3.16.   
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Table 3.16.  Bivariate analysis of need for consent with clinical and 
demographic variables.  
Variable   Need for consent 
(1= yes; 0=others) 
Age t test (df) t (309) = 1.345  
Sig. .180 
Sex Chi square  1.106 
Sig. .293 
Place of residence Chi square 5.86 * 
Sig. .016 
Level of education Chi square 10.50** 
Sig. .005 
Marital status  Chi square .932 
Sig. .334 
Number of children t test(df) t (303) =1.91 
Sig. .057 
Year of diagnosis Chi square 1.228 
Sig. .541 
Stage of tumor a Chi square 6.231 
Sig. .717 
Family history of cancer  Chi square 2.046 
Sig. .153 
Family history of colon cancer  Chi square .011 
Sig. .915 
** Association is significant at the 0.01 level. 
* Association is significant at the 0.05 level. 
 
a Information on stage of tumor was missing for 43.4% of the participants. Nine cells have 
expected count less than 5, results not valid.  
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  A binomial logistic regression model was fitted to examine the effects of place of 
residence, level of education and attitude on the need for consent outcome. 
Binomial logistic regression model was fitted with need for consent (1= yes, 0= 
others) as the outcome variable. It was found that place of residence and level of 
education were the factors determining need for consent. People with bachelor’s 
degree or higher were 5.9 times more likely to prefer consent compared to those 
with high school level education or lower (p<0.05). Similarly, patients with lower 
than a bachelor’s degree were 6.9 times less likely to think they need informed 
consent than those with a bachelor’s degree or higher (p<0.05). Patients living in 
urban areas were 1.7 times more likely to think a separate consent was required 
than those in rural areas (p<0.05). Factors such as age, sex and attitude were not 
predictive of the participants’ preference for consent. The Parameter estimates are 
given in Table 3.17.  
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Table 3.17. Regression parameters of need for consent by place of residence 
and level of education.  
Variable   Sig.  OR      95% CI 
Lower  Upper  
Rural   .042 1.707 1.019 2.861 
Urban  . . 1 . . 
High school 
certificate or lower  
  .019 5.958 1.337 26.548 
Trade school/non-
university 
program/some 
university 
  .012 6.892 1.537 30.907 
Bachelor’s degree 
or higher.  
 . . 1 . . 
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3.4 Chapter summary  
  The support and positive attitude of the participants towards universal tumor 
screening was evident from the analyses presented in this chapter. The multivariate 
regression analysis showed that irrespective of age or clinical characteristics, 
participants were favourable towards universal screening for LS. The information 
obtained regarding opinion on consent protocols and the education needs of 
patients will provide critical information to develop a screening program in 
Newfoundland and Labrador. A deeper understanding of the implications of the 
results of this study is detailed in the next chapter.  
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CHAPTER 4  
 
 
DISCUSSION 
   This chapter begins with a discussion of the study sample, followed by a 
discussion of the survey results. The strengths and limitations of the study are 
described. The chapter concludes with a review of the implications of this research 
and suggestions for future studies.  
 
4.1 Introduction  
  Colorectal cancer (CRC) is a leading cause of mortality and morbidity in Canada. 
Approximately 3-5% of CRC is due to Lynch Syndrome (LS), making it the most 
common type of familial colon cancer. Newfoundland and Labrador (NL) has the 
highest incidence of CRC and the highest rate of CRC death in Canada (Public 
Health Agency of Canada, 2015).  Moreover, NL has the highest frequency of 
familial colon cancer in the world (Green et al., 2007; Woods et al., 2005). In this 
province, identifying individuals at risk of having LS is therefore particularly 
important. Identification of high-risk individuals by conventional family history 
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criteria can be ineffective due to low reliability; that is, a significant number of 
high-risk individuals are missed (Berg et al., 2009). Universal tumor screening for 
LS for all newly diagnosed CRC patients has been recommended by several 
international groups and guidelines and is now standard of care in the US and 
elsewhere (Berg et al., 2009; Bonis et al., 2007; Giardiello et al., 2014; Provenzale 
et al., 2016; Weissman et al., 2012). However, access to universal tumor screening 
is variable across Canada. Understanding the perspectives of eligible patients 
regarding attitudes towards tumor screening and their willingness to take part in 
screening will be critical to the successful implementation and conduct of a 
universal screening program. This study explored the perspectives of patients with 
colon cancer in NL towards universal tumor screening for LS. In particular, their 
attitude towards a screening program, willingness to participate, thoughts on 
communication with both family members and healthcare professionals, and their 
beliefs on the type of informed consent needed for tumor screening (or indeed, 
whether it was needed at all).  The project was conceived directly in response to 
local discussion about the feasibility of establishing a tumor screening program in 
NL.    
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4.2 Sample and representativeness  
  The study response rate was 47%. This response rate is consistent with other 
research utilizing postal surveys with patients with colon cancer specifically, and 
cancer generally (Asch, Jedrziewski, & Christakis, 1997; Hornik Robert, Fraze 
Taressa, & Kelly Bridget, 2010). The response rate is higher than surveys of 
similar populations in the US (Hornik Robert et al., 2010; Smith et al., 2007). The 
good response rate may be indicative of the interest local patients have on the topic 
and helped ensure an adequate sample size for analyses.  
  Survey respondents were representative of the target population across all 
demographic variables, except age. The mean age of the respondents was slightly 
lower than the non-respondents, consistent with the available literature (Hornik 
Robert et al., 2010; Smith et al., 2007). This could be due to an increased difficulty 
in completing the survey because of the morbidity associated with a cancer 
diagnosis and advancing age, or that younger individuals are more interested in 
participating in the survey. We note, however, that the difference in age was minor 
(roughly 71 years versus 69 years).  
  The male-female ratio, as well as the rural-urban ratio of the participants, were 
comparable to the target population. Regarding level of education, over half of the 
participants in this study had a high school certificate or lower. In general, those 
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with higher education levels are more likely to respond to surveys than those with 
lower levels of education (Curtin, Presser, & Singer, 2000). For example, a similar 
survey study in the US exploring CRC patients’ beliefs about universal screening 
reported that most participants were highly educated (Hunter et al., 2015). 
However, the range of education levels represented in our sample corresponds to 
the level of education of the average Newfoundland resident (Etchegary et al., 
2013). We believe this has helped ensure a more representative sample from the 
population.   
  The majority of the participants had a positive family history of cancer. This 
finding was unsurprising and corresponds to the high prevalence of cancer in the 
province (Public Health Agency of Canada, 2015). Less than half of the 
respondents reported a positive family history of colon cancer specifically, also 
consistent with other Newfoundland studies (Green et al., 2007). In all, survey 
respondents were representative of patients in Newfoundland with colon cancer, 
and there were no important differences between respondents and non-respondents.   
 
4.3 Prior knowledge and risk perception  
 Study participants had low levels of knowledge regarding inherited forms of colon 
cancer and universal screening. This finding is consistent with the existing 
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literature (Etchegary et al., 2013; Manne S. et al., 2007). The knowledge levels of 
participants with CRC were lower than those of patients with known LS mutations. 
This was expected as patients with known LS would have received detailed genetic 
counselling and therefore more likely to be familiar with inherited forms of colon 
cancer (Etchegary et al., 2009; Hunter et al., 2015). Our study population included 
all patients with CRC, irrespective of family history or known mutations, as this 
would be the target population for a universal screening program. Additionally, our 
participants were not highly educated, with most of them having a high school 
certificate or lower. The findings of this study demonstrate low knowledge levels 
among the general population and the need for awareness among the general public 
if a tumor screening program were to be implemented. Thus, there is a critical need 
for the development of patient-centered educational materials about universal 
tumor screening.  
  Study findings revealed low perceived risk of developing colon cancer among the 
participants. Risk perception was significantly correlated with family history of 
cancer and level of education. Participants with a positive family history of cancer 
reported a higher risk perception, whereas those with a higher level of education 
reported a lower risk perception. Level of perceived risk was consistent with other 
studies (Croyle & Lerman, 1993; Hunter et al., 2015), but is lower than that found 
in the literature related to Lynch syndrome risk perception and genetic testing 
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(Watkins et al., 2011). Studies suggest that knowledge about genetic cancer is 
associated with an increased risk perception (Seven, 2017). The lower education 
level, in addition to low levels of prior knowledge of inherited cancer in our 
sample, could help explain the lowered risk perception observed in our study. 
While NL has a high incidence of familial cancers, (Green et al., 2007) low 
knowledge levels observed in this study suggest the need for better education and 
the need for more awareness about Lynch Syndrome in the province. It is 
interesting to note that even with low risk perception and low knowledge levels, 
surveyed patients were highly willing to undergo screening and had a positive 
attitude towards it. 
 
4.4 Patient attitude and willingness to undergo screening.  
  Attitude of the patients and their willingness to participate in a tumor screening 
program are both critical to identifying individuals at risk of having Lynch 
syndrome (LS) (Daudelin, Lehoux, Abelson, & Denis, 2010; Etchegary, 2014). 
Our study results suggest that patients with colon cancer in Newfoundland and 
Labrador (NL) have a positive attitude towards universal screening and are willing 
to have their tumors screened if such a program were to be offered in the province. 
Patients agreed with the potential benefits of the program. Specifically, they agreed 
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that their family could benefit from such a screening test, and that the results could 
help them plan their future. They also agreed that a screening program for LS 
would be beneficial to high risk individuals and should be available to anyone who 
has had colon cancer. These findings are consistent with the results of the handful 
of studies to report patients’ attitudes towards universal tumor screening (Hunter et 
al., 2015; Manne S. et al., 2007) and reflects the overall positive attitude towards 
genetic screening tests (Etchegary et al., 2009; Etchegary, 2014; Kessler et al., 
2005; Meisel et al., 2013; Scuffham, McInerny-Leo, Ng, & Mellick, 2013). Of 
note, the majority of the participants did not consider paying for the test as a 
barrier, in contrast to the US study (Hunter et al., 2015). Similarly, only a small 
percentage of participants noted concerns about health or life insurance. While this 
finding was consistent with existing evidence, concerns about health and life 
insurance implications of a screening test are valid concerns for some patients as 
evidenced in studies conducted across Canada and elsewhere (Esplen et al., 2001; 
Lerman, 1994). The relatively low concerns about barriers to tumor screening 
observed in this sample is likely the result of Canada’s Universal health care 
system and its extensive coverage. Research confirms that Canadian patients are 
not generally as worried about insurance or the cost of medical care compared to 
their counterparts in other parts of the western world (Blendon, Leitman, Morrison, 
& Donelan, 1990; Ridic, Gleason, & Ridic, 2012). Our findings on other barriers 
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such as ‘people should not have their tumors screened if they don’t ask for it’ and 
‘I do not want know about any genetic risks I might have’ are consistent with 
similar studies (Hunter et al., 2015; Manne S. et al., 2007). We found that patients 
with a higher risk perception had a less positive attitude towards screening. This 
finding was also in line with those found in the literature (Manne S. et al., 2007). It 
is possible some patients would have a fatalistic attitude towards cancer risk, 
believing that nothing can be done to change the risk and therefore not seeing 
value in a possible risk-reducing or preventative measure (Claassen et al., 2010; 
McClure, 2002). The potential relationship between fatalistic attitudes and 
behavioural modification after the identification of a genetic risk has been studied 
with inconclusive results. Some studies found that patients see genetic risk 
information as uncontrollable and are therefore less likely to engage in screening 
or preventative behaviors (Senior, Marteau, & Peters, 1999). Others have found 
limited /little evidence as to its impact on risk reducing behaviour (Collins, Wright, 
& Marteau, 2011; Marteau et al., 2004; Wright, 2006). In our study, the correlation 
between risk perception and unwillingness to undergo the screening test could be 
due to fatalistic attitudes or that some patients may simply fear knowing their 
genetic status (Croyle & Lerman, 1993; Hunt, Davison, Emslie, & Ford, 2000).   
   An overwhelming majority of the participants were willing to have their tumors 
screened if a universal screening program were available in NL. This finding is 
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consistent with existing literature; patients are generally willing to undergo 
screening tests and hold a positive attitude (Hall et al., 2014; Kessler et al., 2005; 
Knight et al., 2015; Manne S. et al., 2007; Meisel et al., 2013; Scuffham et al., 
2013). Unsurprisingly, patients with a more positive attitude towards screening 
were more willing to undergo screening themselves, which is again consistent with 
the findings of other studies (Cameron & Muller, 2009; Etchegary, 2014; Meisel et 
al., 2013; Scuffham et al., 2013). However, a positive attitude does not necessarily 
translate into increased uptake (Cameron & Muller, 2009). As such, we have no 
way of knowing if the positive attitudes observed in this study would actually 
translate into positive tumor screening uptake. However, the favourable attitude of  
patients who have had colon cancer is a necessary first step in the creation of a 
local tumor screening program.  
   The results of this study indicate that younger patients had a slightly more 
favourable attitude towards screening and were more willing to undergo screening 
themselves. This trend has been observed in studies examining the factors 
associated with MSI testing specifically, and genetic testing in general (Etchegary, 
Green, Parfrey, Street, & Pullman, 2015; Shaikh, Handorf, Meyer, Hall, & 
Esnaola, 2017).  This could be due to the extra burden an additional test would 
bring on elderly patients, and suggests the need for more patient education about 
the importance of tumor screening, not only for self, but also other family members 
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(Hall, 2010). In our study, family history of cancer had no correlation with the 
patients’ attitude. It was found that patients with a positive family history 
specifically of CRC, however, were more willing to undergo screening. While not 
a strong correlation, this finding is consistent with the literature (Karlitz et al., 
2015; Kinney et al., 2000). It is interesting to note that in the study by Hunter et al., 
the lack of family history of CRC was the most common reason given by the 
participants to refuse screening (Hunter et al., 2015). The relatively weak 
associations of age and family history of cancer with willingness to undergo tumor 
screening could be a reflection of the lack of variability in the outcome variable: a 
sizable majority of respondents indicated their intention to participate in a tumor 
screening program.  
 We found that patients who were willing to undergo screening were also more 
likely to communicate their results with family members and healthcare 
professionals. Willingness to communicate test results is also a key factor in the 
success of a tumor screening program. The findings related to communication are 
discussed in the following section.  
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4.5 Communication  
  It was clear from our study that patients with a favourable attitude and willingness 
to undergo screening were more likely to communicate their results with family 
members and healthcare professionals. This finding is consistent with the other 
studies in the literature (Esplen et al., 2001; Graves et al., 2014; J. Hunter et al., 
2017; Katz et al., 2017; Leenen et al., 2016; Pentz et al., 2005; Stoffel et al., 2008). 
Patients who had prior knowledge about Lynch Syndrome and universal screening, 
and those of a younger age, with higher education levels, and an urban residence 
were more inclined to communicate their results. Graves et al. studied the 
psychological, communication, and behavioral outcomes following an offer to 
learn MMR results among patients in a Colon Cancer Family registry. They 
examined the participants’ views on communication of their MMR test result 
with family members. Most of the participants, whilst having a higher risk 
perception, had disclosed their test results with their family members and 
healthcare professionals. Those with a family history of CRC and prior 
knowledge were more likely to discuss this with their doctor (Graves et al., 
2014). In a qualitative study of HNPCC families, Pentz et al. similarly found that 
HNPCC families supported the idea of communication with family members 
about their genetic risk, namely to facilitate early screening among at risk 
individuals. They also found that while the probands were the main informants, 
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healthcare professionals also played an important role in the dissemination of the 
information to the family members (Pentz et al., 2005). In our survey, more than 
half of the participants thought that they would need help from a healthcare 
professional in communicating to their family about the results of the screening 
test. This finding is also consistent with other studies (Kass, Sugarman, Faden, & 
Schoch-Spana, 1993) and highlights the critical need for trained healthcare 
professionals in a tumor screening program, or at least for the development of 
educational resources for use by healthcare professionals involved in tumor 
screening programs.  
   Stoeffel et al. found no demographic factors to be associated with 
communication in a study among patients who fulfilled family history criteria for 
LS and had undergone genetic testing (Stoffel et al., 2008). In the current study, 
participants had low prior knowledge and had never been screened for LS 
mutations. Even so, the clear majority of participants expressed an intention to 
communicate their results with family members and healthcare professionals. 
Study findings suggest that educational initiatives about the value of tumor testing 
for families or communication support may be needed for particular subgroups of 
the population, such as older patients, those living in rural areas or those with 
lower levels of education. The findings highlight clear expectations of patients for 
the role of healthcare professionals in helping them communicate with family 
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members and suggest resources that would be necessary in developing a tumor 
screening program for our province.  
   There are several identified barriers to communication with family as well. They 
include factors such as pre-existing relationship dynamics within the family, 
uncertainty of the risk, and varied understanding of the implication of the genetic 
risk on the relatives (Forrest et al., 2003). Healthcare professionals and genetic 
counselors need to be cognizant of these barriers from the patient perspective so 
that effective communication with the at-risk relatives can be established. Several 
studies have explored various approaches to facilitate communication with family 
members regarding a genetic risk. One of them is providing the patients with 
printed informational materials and subsequent follow up support (Gorrie, 
Archibald, Ioannou, Curnow, & McClaren, 2018). A ‘family mediated approach’ 
in which the communication methods to the family members are discussed with the 
patients during genetic counseling following diagnosis, and a printed informational 
letter for the relatives provided to the patients, has also been found to be 
satisfactory and effective by patients in the Netherlands (Leenen et al., 2016).  
Another strategy that has been proposed is a telephone-based, two-step approach, 
in which patient education and support are given through telephone calls from 
counselors, along with printed informational sheets for healthcare providers and 
patients themselves (Graves et al., 2014). These strategies, coupled with the 
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findings and insights from our study, could help formulate counseling and 
communication policies that would benefit the patients and aide them in 
communicating their results to family members and relatives. This, in turn, could 
facilitate genetic screening of the relatives, frequent cancer screening tests to detect 
early cancer if needed, and eventual lowering of the mortality and morbidity due to 
Lynch Syndrome.   
 
4.6 Need and preferred form of consent. 
    
  A key aim of the current research was to explore patients’ perspective on the need 
for (and preferred form of) informed consent for tumor testing. Informed consent 
involves educating the patients about the risks, benefits and alternatives to the 
procedure or test prior to the test, thereby enabling them to make informed 
decisions about their health; it also has ethical and legal ramifications (Annas, 
1977; Faden, 1986). Explicit informed consent is required prior to colon cancer 
screening procedures, including colonoscopy. However, there is no similar 
mandate of consent requirement in testing biopsy samples or resected tissue 
samples (Feld, 2002). The consent model often used in this situation is of implied 
consent. That is, testing takes place unless patients explicitly decline. Genetic tests 
require explicit informed consent because of their implications in the patient’s, as 
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well as their families’, health and future (Feld, 2002). There are no universally-
accepted guidelines for consent protocols of universal screening for LS and it is the 
subject of debate in the literature (Beamer et al., 2011; Shipman et al., 2013). MSI 
testing can be considered a genetic test, and as such, the EGAPP Working Group 
(EWG) suggests the use of informed consent prior to MSI testing, whilst noting the 
contrasting views from the literature (Berg et al., 2009). IHC testing is not viewed 
as ‘genetic testing’ and thus, informed consent is not a requirement (Berg et al., 
2009). Some authors disagree, suggesting IHC testing has more in common with 
genetic tests because of the information the test provides (Chubak et al., 2011). 
Chubak et al. conclude that explicit informed consent is not required for MSI 
testing because the testing does not affect patients in “potential harmful ways” that 
would necessitate an informed consent. From a medical and public health ethics  
point of view, debate exists about protecting patient autonomy for the patients who 
test positive and the fear of causing unnecessary stress and anxiety for the patients 
who test negative. The need for, and form of, informed consent for the cascade 
screening of family members of patients who test positive has largely not been 
addressed. Furthermore, resources, personnel and time needed for building consent 
protocols and obtaining them are also of significant concern (Bombard et al., 2017; 
Zeps, Iacopetta, Schofield, George, & Goldblatt, 2007). To date, the consent 
protocols regarding these screening tests are not well established and are widely 
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debated (Bombard et al., 2017; Chubak et al., 2011; Janet & Marc, 2011; Shipman 
et al., 2013).  
       Given the reflexive nature of tumour screening and the significance of cascade 
testing of the family members which would significantly impact the success of the 
screening program, the need for consent and the consent protocol for universal 
screening, we suggest that patient views on consent protocols are a critical piece of 
information in the planning of a universal tumor screening program.  
   Patient perspectives on consent models for tumor screening have not been 
researched extensively, and this study aimed to contribute to filling that gap.  
Contrary to most current practice, our results indicate that the majority of patients 
believed an informed consent was required for universal screening. This finding is 
consistent with the few other studies that have examined patient perspectives on 
consent in this context (Ormond et al., 2007; Wolf & Schorling, 2000). The finding 
is in contrast to the perspectives of many healthcare providers on informed consent 
for tumor screening. For example, none of the 29 National Cancer Institute–
designated cancer centers that participated in a survey exploring Lynch Syndrome 
screening practices using MSI or IHC required an informed consent from the 
patients (Beamer et al., 2011). Several other studies have also suggested that a 
consent is not necessary for screening for Lynch Syndrome (Gaff, Rogers, & 
Frayling, 2007; Janet & Marc, 2011). Bombard et al. found that healthcare 
 127 
 
professionals in Canada did not see the need for obtaining consent for screening for 
LS in a qualitative study, but did agree with giving patients the choice of opting 
out of further confirmatory mutation testing (Bombard et al., 2017). In the current 
study, highly educated patients were more likely to believe informed consent is 
required before a universal screening test. This result is consistent with the existing 
evidence: namely, that educated patients prefer to be in control of their health and 
to participate in decision making (Degner & Sloan, 1992). In contrast, it has been 
observed in a UK study that people with low education levels were more likely to 
expect to be asked for explicit consent (Riordan et al., 2015). We found that the 
belief on the need for informed consent was not associated with the attitude 
towards the screening test or willingness to undergo screening. These findings are 
also in agreement with the existing evidence (Degner & Sloan, 1992; Riordan et 
al., 2015). This, coupled with the highly positive attitude of the participants 
towards tumor screening, highlights the interest of the patients in understanding 
their genetic risk and their desire for active participation in decision making about 
tumor screening. Our findings suggest that patients prefer a written informed 
consent taken at the same time as surgical consent. These findings have immense 
practical value in the implementation of the screening program, but they also raise 
serious practical and logistical concerns regarding the content of consent materials 
and the role of healthcare professionals in gaining consent, particularly in the 
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existing climate that tends towards non-requirement of informed consent in 
screening for LS. Serious thought will need to be taken by decision makers 
responsible for planning tumor screening programs about consent protocols that 
are acceptable to patients. In the light of present findings of patient preference for 
consent, an opt-out strategy could be a practical suggestion  Even though there is 
some difference of opinion among healthcare providers whether an opt-out option 
be provided before or after the screening test, it is generally agreed upon that 
seeking such a consent could be appropriate considering the minimal constraints on 
resources for its implementation (Bombard et al., 2017).  
 
4.7 Informing and educating patients 
     Expert guidance on implementing universal tumor screening programs for 
Lynch syndrome (LS) suggests that educating patients and families is a crucial step 
(Berg et al., 2009; Forrest et al., 2003; Provenzale et al., 2016). In the current 
study, participants wanted to be informed about screening for LS at the time of 
diagnosis, by almost any healthcare professional. Most often, patients indicated 
their surgeons or primary care physicians could talk to them about universal 
screening for LS. Given the scarcity of genetic counsellors and long wait times for 
counselling services in NL, this finding has practical implications (Parfrey et al., 
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2017). There is evidence suggesting the public expect their primary care physician 
to know about genetics and to communicate potential genetic risks (Feero, 2008; 
Miller et al., 2010). Pre-test counselling/ discussion with the patients could be 
undertaken by trained nurses, surgeons, or family doctors, thereby utilizing scarce 
counseling resources wisely. The CanIMPACT (Canadian Team to Improve 
Community-Based Cancer Care along the Continuum) study found that Primary 
Care Physicians (PCP) understand their role and express interest in genomics and 
personalized medicine. However, only 53% of the participating PCPs were 
knowledgeable about genetic testing for CRC (Carroll et al., 2016). Strategies to 
increase awareness and knowledge about genetic services and genomics and 
collaboration with genetic counselors and geneticists should be incorporated in 
optimizing the role of PCPs in universal screening. Similarly, surgeons also play a 
role in communicating and educating the patients. As they are the first healthcare 
providers patients often see after their initial diagnosis, the burden of providing 
adequate information on Lynch Syndrome, screening and its implications could fall 
with surgeons. It has been found that healthcare providers hold a favourable 
attitude towards universal screening. HCPs also understand the importance of 
patient education at an early stage as well as creating awareness in the community 
(Bombard et al., 2017). Resource allocation for training other healthcare 
professionals on tumor screening for LS and informing patients is an important 
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issue that needs to be addressed by policy and decision makers. (Rahimzadeh & 
Bartlett, 2014; Watson, Shickle, Qureshi, Emery, & Austoker, 1999).  
   We found that patients prefer educational materials to be provided about 
universal tumor screening and LS prior to screening tests. Educating patients and 
creating awareness is agreed upon by healthcare professionals and policy makers 
(Beamer et al., 2011; Bombard et al., 2017; Manne S. et al., 2007), but as of yet, no 
common set of guidelines or materials are universally accepted and used. EGAPP 
guidelines recommend providing educational materials for all CRC patients, as 
well as their relatives (Berg et al., 2009). The low levels of prior knowledge and 
awareness in the current study population stresses the importance of informing and 
educating patients. Several studies have underscored the importance and 
effectiveness of educational materials in LS screening, which range from educating 
and enabling the patients themselves, to communication with and educating the 
family members (Dilzell, Kingham, Ormond, & Ladabaum, 2014). Such 
facilitation of communication with the aid of educational materials could be useful 
in cascade screening of the family members resulting in early identification and 
subsequent preventative measures (Dilzell et al., 2014). Programs such as the 
Lynch Syndrome Educational Workshop (LSEW) and Lynch Syndrome Patient 
Advocacy Network (LSPAN) support group have been found to be satisfactory by 
patients. The participating patients expressed preference for topics including 
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family communication, genetic testing decisions, and support groups (Corines et 
al., 2017). Our findings, together with the existing knowledge, could help in 
formulating program guidelines, namely the development of educational materials 
and training programs for healthcare professionals who might be involved in tumor 
screening programs.  
  This is the first study conducted in the province about patients’ attitudes towards 
universal tumor testing in the context of LS. Given the high rate of familial colon 
cancer in the province, and the growing endorsement of universal tumor testing as 
an effective strategy for identifying high-risk individuals, study results provide 
invaluable information for the healthcare professionals and policy makers who are 
discussing this possibility locally. Our results are consistent with the studies 
conducted in the US and elsewhere (Hunter et al., 2015; J. Hunter et al., 2017; 
Manne S. et al., 2007) and reveal the importance of understanding patient 
perspectives on tumor screening. 
 
4.8 Limitations of the study 
  There are a few limitations to consider in this study. The questionnaire developed 
by the research team was not pilot tested. However, it was reviewed by our patient 
partner for the flow of items, readability, length and content. Changes were made 
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based on his review, as well as the review by a gastroenterologist and gynaecologic 
oncologist, both of whom have worked with families affected by LS. Despite the 
lack of pilot testing, no research has been conducted in this area in the province 
and the study’s key objective was to obtain patient perspectives, which we believe 
was achieved. While adequate, the internal consistency of the attitude scale (as 
measured by Chronbach’s alpha) was low. Further, while we created attitude and 
communication scales for purposes of analysis, these were not subject to formal 
scale validation. Given the pilot nature of this work, and the need to collect patient 
opinion data before any tumor testing program started in the province, we believe 
the results have descriptive value. However, we recommend formal scale 
validation in future work should similar scales be used. The eligible participants 
from the cancer registry included patients diagnosed from 2014-2016, which 
excludes the views of patients diagnosed before or after that period. The research 
team had no control over the potential population, as the Cancer Centre decided 
these were the years to be included. While we have no reason to believe that 
attitude or willingness would be different if patients were diagnosed in other years, 
we cannot rule out the possibility. Our study did not have an age limit set for the 
eligibility criteria. The mean age of participants was around 70, and this could 
affect generalizability of the results. However, with recent studies suggesting all 
newly diagnosed CRC patients undergo screening irrespective of age, we think our 
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eligibility criteria were inclusive and more representative of the stakeholder 
population in our province. The current study also did not include the perspectives 
of family members; however, a positive tumor screening test has notable 
implications for relatives. Their perspectives are also critically important, and we 
suggest future research explore the opinions of this population. Lynch syndrome 
(LS) is associated with a higher incidence of cancer in extra colonic sites, 
including the endometrium for which universal screening is recommended. In this 
current study, the perspectives of endometrial cancer patients are not explored. 
Future studies might also explore the attitudes of these patients with LS-associated, 
extra colonic malignancies. All surveys are liable to non-response bias which 
occurs when the responders and non-responders differ in certain ways including 
socio-demographic factors, behaviour and attitude. Those who have responded to 
the survey could have had more favourable attitudes than the non-responders, 
thereby overestimating our findings and lowering the external validity of the study. 
Non-response bias is different from volunteer bias, in which the people who 
volunteered to participate in the survey (completed the survey) systematically 
differed from the population. It is possible that people who participated in the 
survey had more favourable attitudes than the target population. The sequencing of  
survey items (e.g., “People should not have their tumours screened if they don’t 
ask for the test”, before items on the need for informed consent in the 
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questionnaire) could have primed the participants about expectations for consent, 
thereby affecting response to the consent items. We cannot rule out this possibility 
and it is a limitation of the study. We also excluded the patients who died prior to 
the survey. It is possible that these patients (prior to death) and/or their families, 
could hold extreme views about the benefits/risks of tumor screening that would 
not be representative of the rest of the group. Finally, the extreme lack of 
variability in the outcome variable (willingness to take part in a tumor screening 
program) could have skewed the results and reduced the validity of the results. We 
note however, that planners of a tumor screening program in the province would 
need this key information on interest from the general public.  
 
4.9 Strengths of the study 
   This is the first study of its kind exploring the perspectives of patients towards 
universal screening for LS in the province. To our knowledge, there are no 
published studies in Canada about patient views. This is the main strength of the 
current study, addressing the existing knowledge gap in this area and providing 
important patient perspectives that should be helpful in planning a tumor screening 
program in the province. While limited in years, the inclusion of all patients from 
the cancer registry diagnosed during the specified time period helped to avoid 
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sampling bias. One of the strengths of this survey is the good response rate, which 
highlights the interest of the population in this topic. We undertook several steps to 
increase the response rate including reminder mail outs, a personalized cover letter, 
a prize draw, and including postage-paid return envelopes with the survey booklet. 
The high response rate, combined with the low number of missing responses, 
contributed to the quality of the data. Finally, the range of education level in our 
sample was variable and represented the provincial distribution fairly well. Survey 
studies in genetics very often contain highly educated samples. Our sample better 
reflected the patients who would be offered tumor testing, thus increasing the 
generalizability of our results. 
  In this era of patient autonomy and personalized medicine, the role of public 
engagement in research is inimitable (Etchegary & Wilson, 2013).This study 
involves the patients who are the key stakeholders, on two levels, namely patient 
participation and patient engagement. Firstly, this study provides strong descriptive 
answers from patients regarding the practical aspects of the development and 
implementation of a universal screening program. Specifically, when tumor 
screening should be discussed with patients, who should have that discussion with 
patients, what kinds of consent protocols might need to be in place, and what kind 
of educational materials would need to be developed. Secondly, this study engaged 
a patient partner, a person who brought his expertise and experience as a colon 
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cancer survivor. He was involved with the research team from the beginning stages 
of the study. He helped to review the survey and provided valuable input to ensure 
the survey quality and dissemination. He is eager to be involved in the future steps 
as well, including dissemination of results to patients and providers. This aspect of 
patient engagement is one of the main strengths of this study.  
 
4.10 Implications of the research  
   This thesis is part of a larger project, exploring the perspectives of three key 
stakeholder groups about a universal screening program for Lynch Syndrome (LS). 
The other phases address the attitudes of pathologists and genetic counsellors 
across Canada. As stated earlier, Newfoundland and Labrador (NL) has the highest 
incidence of familial colon cancer in the world (Green et al., 2007). Despite 
universal tumor screening being recommended by several international 
organizations and governments, such a program is lacking in NL. However, the 
research team is aware of discussion locally and pending funding, there is a 
willingness to develop such a program for the province. The findings of this study 
have real world implications in implementing a universal screening program for LS 
in NL.  Our findings on patients’ desire for informed consent could provide insight 
into developing educational materials and consent protocols in the province. In a 
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province with a significant rural population and few genetics healthcare 
professionals, involving primary care physicians and surgeons in discussions with 
patients about Lynch syndrome would also have implications for resource 
allocation. We acknowledge the deficiencies in resources and budgetary 
constraints in implementing a screening program in the province. However, we 
suggest these considerations for decision makers as a starting point based on the 
results of this study: a) Building awareness of familial colon cancer including LS, 
its prevalence in the province and its wider implications; b) A deeper 
understanding of universal tumour screening and its significance in the province 
given the prevalence of CRC and familial colon cancer in NL; c) Devising program 
guidelines based on stakeholder perspectives (patients, healthcare providers, 
genetic counselors) obtained from the findings of the current study as well as those 
exploring perspectives of other stakeholders; d) Considering the low knowledge 
levels among the participants about LS and screening, we would suggest 
developing detailed patient educational materials that could be made available in 
various ways including doctors’ office, online, etc.; e) Developing and 
implementing policy guidelines and consent protocols considering perspectives of 
patients and other stakeholders. 
   The study also attempts to fills a knowledge gap in addressing the perspectives of 
patients regarding attitudes towards universal screening, contributing to the 
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academic discourse. However, further research can be done to validate the survey 
and use it to explore the perspectives of stakeholders in other parts of the country. 
Future studies focusing on the perspectives of the family members of colon cancer 
patients, and on that of patients with LS-associated extracolonic cancers need to be 
undertaken.  
  We plan to disseminate the findings of the study by conducting workshops across 
the province, helping to raise awareness about Lynch syndrome and tumor 
screening. Frequent cancer screening and other preventative measures for the 
patients and their families will help lower the mortality and morbidity associated 
with Lynch Syndrome.  
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4.11 Conclusion  
    Universal screening for LS using MSI or IHC testing of all newly diagnosed 
CRC patients is beneficial in early identification of at-risk individuals. 
Identification is necessary to allow appropriate cancer screening/ surveillance and 
preventative risk-reducing measures for this high-risk population. Our study found 
that CRC patients have a favourable attitude towards universal tumor screening for 
LS and are willing to have their tumors screened if such a program were available. 
Their perspectives on informed consent, the provision of educational materials and 
the potential requirement of help from healthcare professionals could help planners 
of a screening program for LS for the province and hopefully optimize the 
screening rates. A universal tumor screening program could ultimately help reduce 
the high mortality and morbidity of familial colon cancer in the province. Further 
research by exploring the perspectives of genetic counselors, pathologists and 
family members of the patients would be beneficial in expanding the knowledge 
base and identifying key concerns.    
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A p p e n di x A  
S u r v e y Q u esti o n n ai r e   
 
T his s ur v e y h a s t hr e e s e cti o ns. T h e first s e cti o n is a b o ut y o ur k n o wl e d g e a n d u n d erst a n di n g 
of a h er e dit ar y f or m of c ol o n c a n c er, k n o w n as L y n c h S y n dr o m e. T h e s e c o n d p art is a b o ut 
y o ur attit u d e a n d o pi ni o ns a b o ut s cr e e ni n g f or t his g e n eti c f or m of c ol o n c a n c er, a n d t h e l ast 
s e cti o n c o n sists of a f e w q u esti o ns a b o ut y o urs elf. Pl e as e f e el fr e e t o i g n or e a n y q u esti o n y o u 
d o n ot w a nt t o a ns w er. T h er e ar e n o ri g ht or wr o n g a n s w ers h er e. W e ar e o nl y i nt er e st e d t o 
k n o w w h at y o u t hi n k a b o ut t hi s s cr e e ni n g t est. W e t h a n k y o u f or y o ur ti m e a n d a p pr e ci at e 
y o ur eff ort s.                                               
 
S E C TI O N 1  
1 .  B ef or e t o d a y, h o w m u c h h a d y o u h e ar d a b o ut g e n eti c or i n h erit e d f or m s of c ol o n 
c a n c er ?   
  Pl e as e i n di c at e y o ur a ns w er fr o m t h e f oll o wi n g.  
  I ha d n e v er h e ar d a b o ut it  
  I h a d h e ar d a littl e  
  I h a d h e ar d s o m e d et ail s, b ut n ot a l ot  
  I h a d h e ar d a f air a m o u nt a b o ut it  
  I h a d h e ar d a l ot  
 
    F or q u esti o n 2, pl e as e i n di c at e h o w m u c h y o u a gr e e wit h t h e f oll o wi n g st at e m e nt.  
2. I h a v e al w a y s s u s p e ct e d I w o ul d g et c a n c er, b e c a u s e it r u n s i n m y f a mil y.  
    Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
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W h e n a p ati e nt wit h c ol o n c a n c er u n d er g o e s s ur g er y as p art of t h eir tr e at m e nt, t h eir c ol o n 
c a n c er t u m or is t est e d i n t h e l a b t o h el p i d e ntif y t h e st a g e of c a n c er. T his i s r o uti n el y d o n e. 
A n ot h er t est c a n al s o b e d o n e o n t h e t u m or t o fi n d o ut if a p ati e nt i s at ris k f or a g e n eti c 
f or m of c ol o n c a n c er c all e d L y n c h s y n dr o m e. T his i s s o m eti m es c all e d ‘ U ni v ers al t u m or 
s cr e e ni n g’. If t h at t est is a b n or m al, f urt h er t e sti n g c a n b e d o n e, i n cl u di n g a bl o o d t est t o 
c h e c k f or g e n eti c ri s k of L y n c h s y n dr o m e. At t his ti m e, u ni v ers al t u m or s cr e e ni n g is n ot 
r o uti n el y d o n e i n N e wf o u n dl a n d a n d L a br a d or.   
 
 3. B ef or e t o d a y, h o w m u c h h a d y o u h e ar d a b o ut ‘ U ni v er s al t u m or s cr e e ni n g f or L y n c h 
S y n dr o m e’ ?  
     Pl e as e i n di c at e y o ur a ns w er fr o m t h e f oll o wi n g.  
   I h a d n e v er h e ar d a b o ut it  
   I h a d h e ar d a littl e 
   I h a d h e ar d s o m e d et ail s, b ut n ot a l ot  
   I h a d h e ar d a f air a m o u nt a b o ut it  
   I h a d h e ar d a l ot      
 
S E C TI O N 2  
 
F or q u esti o ns 4 -1 2 pl e as e i n di c at e h o w m u c h y o u a gr e e wit h e a c h st at e m e nt.  
4. U ni v er s al t u m or s cr e e ni n g of c ol o n c a n c er t u m or s w o ul d b e u s ef ul f or i d e ntif yi n g hi g h 
ri s k i n di vi d u al s.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
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5. M y f a mil y c o ul d b e n efit fr o m t hi s t e st.   
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
6. I w o ul d n ot t a k e a t u m or s cr e e ni n g t e st it if I h a d t o p a y f or it.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
7. P e o pl e s h o ul d n ot h a v e t h eir t u m or s s cr e e n e d if t h e y d o n’t a s k f or t h e t e st.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
8. T h e r e s ult of a t u m or s cr e e ni n g t e st c o ul d h el p m e pl a n m y f ut ur e.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
  
 1 7 3  
 
 
9. T h e r e s ult of a t u m or s cr e e ni n g t e st c o ul d h el p m e pl a n m y f ut ur e.  
   Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e   
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
1 0. I a m c o n c er n e d a b o ut a n y di s cri mi n ati o n I c o ul d f a c e b a s e d o n t h e t e st r e s ult.  
     Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
1 1. I d o n ot w a nt t o k n o w a b o ut a n y g e n eti c ri s k s I mi g h t h a v e. 
    Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
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1 2. T h e t e st s h o ul d b e a v ail a bl e t o a n y o n e w h o h a s h a d c ol o n c a n c er a n d wi s h e s t o h a v e 
i nf or m ati o n a b o ut hi s / h er ri s k of i n h erit e d f or m s of c ol o n c a n c er.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e.  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
1 3. If a t u m or s cr e e ni n g pr o g r a m f or L y n c h S y n dr o m e w er e t o b e off er e d i n 
N e wf o u n dl a n d a n d L a br a d or, h o w willi n g y o u mi g ht b e t o h a v e y o ur t u m or s cr e e n e d ?  
Pl e as e i n di c at e y o ur a ns w er i n a s c or e fr o m 1 t o 5, 1 b ei n g “ d efi nit el y n ot willi n g ” t o 5 b ei n g 
“ D efi nit el y willi n g ”  
  1. D efi nit el y n ot willi n g  
  2. N ot willi n g  
  3. N ot s ur e  
  4. Willi n g  
  5. D efi nit el y willi n g  
      
1 4. W o ul d y o u b e willi n g t o di s c u s s y o u r t e st r e s ult wit h a n y of y o ur d o ct or s or ot h er 
h e alt h c a r e pr o vi d er s t o g ui d e y o ur f ut ur e c a r e or tr e at m e nt ?  
Pl e as e i n di c at e y o ur a ns w er i n a s c or e fr o m 1 t o 5, 1 b ei n g “ d efi nit el y n ot willi n g ” t o 5 b ei n g 
“ D efi nit el y willi n g ”  
  1. D efi nit el y n ot willi n g  
  2. N ot willi n g  
  3. N ot s ur e  
  4. Willi n g  
  5. D efi nit el y willi n g  
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F or t h e f oll o wi n g q u esti o ns 1 5 -1 8, pl e a s e i n di c at e h o w m u c h y o u a gr e e wit h e a c h 
st at e m e nt.  
1 5.  I w o ul d t al k t o m y f a mil y m e m b er s a b o ut t h e r e s ult s of a t u m or s cr e e ni n g t e st d o n e 
o n m y  t u m or. 
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
1 6. I w o ul d n e e d h el p f r o m a h e alt h c ar e pr of e s si o n al t o di s c u s s t h e r e s ult s of a s cr e e ni n g 
t e st wit h m y f a mil y m e m b er s.  
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
1 7. I u n d er st a n d t h e i m pli c ati o n s f or m y f a mil y m e m b er s of a t u m or s cr e e ni n g t e st o n m y 
t u m or. 
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h e r a gr e e n or dis a gr e e 
  4. A gr e e  
  5. Str o n gl y a gr e e  
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1 8. I w o ul d e n c o ur a g e m y f a mil y m e m b er s t o l e a r n m or e a b o ut t h e i m pli c ati o n s of a 
t u m or s cr e e ni n g t e st d o n e o n m y t u m or . 
Pl e as e i n di c at e y o ur a ns w er i n s c or e fr o m 1 t o 5, 1 b ei n g str o n gl y dis a gr e e t o 5 b ei n g 
str o n gl y a gr e e  
  1. Str o n gl y dis a gr e e  
  2. Dis a gr e e  
  3. N eit h er a gr e e n or dis a gr e e  
  4. A gr e e  
  5. Str o n gl y a gr e e  
 
W h e n p ati e nts wit h c ol o n c a n c er ar e a d vis e d t o h a v e s ur g er y b y t h eir d o ct or, t h eir c o ns e nt is 
n e e d e d t o all o w s ur g er y t o h a p p e n. T his c o n s e nt als o  i n cl u d es t e sti n g a t u m or s a m pl e f or t h e 
st a g e of c ol o n c a n c er. S cr e e ni n g a c ol o n c a n c er t u m or t o fi n d o ut if a p ati e nt is at ri s k f or 
g e n eti c or i n h erit e d f or m of c ol o n c a n c er i s a si mil ar t est t h at c a n b e d o n e usi n g t h e t u m or 
s a m pl e.  
 
1 9. D o y o u t hi n k t h at c o n s e nt s h o ul d b e o bt ai n e d f or t h e t u m or s cr e e ni n g t e st t o i d e ntif y 
p ati e nt s w h o mi g ht b e at i n cr e a s e d ri s k f or i n h erit e d c ol o n c a n c er ?  
  Y es, I w o ul d w a nt t o k n o w w h at t est s ar e b ei n g c o n d u ct e d o n m y t u m or.  
  N o, a c o ns e nt is n ot r e q uir e d t o t est m y t u m or  f or ris k f or i n h erit e d c ol o n 
c a n c er.  
  I a m n ot s ur e.  
 
2 0. If i nf or m e d c o n s e nt i s t a k e n f or t u m or s cr e e ni n g t o i d e ntif y p ati e nt s at ri s k f or 
i n h erit e d c ol o n c a n c er, w h e n d o y o u t hi n k t hi s c o n s e nt s h o ul d b e t a k e n fr o m p ati e nt s ?  
 
  At t h e s a m e ti m e as t h e s ur gi c al c o ns e nt  
  It s h o ul d b e a s e p ar at e c o ns e nt  
  Ot h ers, pl e as e e x pl ai n: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  I a m n ot s ur e  
 
 
2 1. W h o d o y o u t hi n k s h o ul d t al k t o p ati e nt s a b o ut t hi s t u m or s cr e e ni n g t e st ? Pl e a s e 
s el e ct all t h at a p pl y:  
  M y F a mil y d o ct or  
  M y S ur g e o n  
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  M y o n c ol o gi st  
  A g e n eti c c o u ns el or  
  A n y o n e a b o v e, as l o n g as  I a m t ol d a b o ut it  
  I a m n ot s ur e  
 
2 2. W h e n d o y o u t hi n k s o m e o n e s h o ul d t al k t o p ati e nt s a b o ut t u m or t e sti n g f or i n h erit e d 
c ol o n c a n c er ?  
  W h e n p ati e nts first r e c ei v e t h e di a g n osi s of c ol o n c a n c er  
  B ef or e a bi o p s y of t h e t u m or is t a k e n  
  B ef or e s ur g er y  
  Aft er s ur g er y, d uri n g a f oll o w -u p visit  
  Ot h ers, pl e as e e x pl ai n: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  I a m n ot s ur e  
 
 
2 3. W h at t y p e of c o n s e nt s h o ul d b e o bt ai n e d f or t h e t u m or s cr e e ni n g t e st t o i d e ntif y 
p ati e nt s w h o mi g ht b e at i n cr e a s e d ri s k f or i n h erit e d c ol o n c a n c er ?  
  V er b al  
  Writt e n  
  N o n e  
  I a m n ot s ur e   
 
 
2 4. D o y o u t hi n k writt e n e d u c ati o n al m at eri al s s h o ul d b e pr o vi d e d t o p ati e nt s a b o ut 
s cr e e ni n g t h eir t u m or s f or i n cr e a s e d ri s k of i n h erit e d c ol o n c a n c er ?  
  Y es  
  N o  
  I a m n ot s ur e  
  
 
2 5. W h e n d o y o u t hi n k e d u c ati o n al m at eri al s s h o ul d b e pr o vi d e d t o p ati e nt s ?  
  B ef or e t h e d a y of s ur g er y  
  Wit h ot h er i nf or m ati o n gi v e n t o p ati e nts o n t h e d a y of s ur g er y  
  U p o n dis c h ar g e fr o m t h e h os pit al aft er s ur g er y  
  Ot h er, pl e as e e x pl ai n: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
  I a m n ot s ur e  
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S E C TI O N 3  
2 6. W h at i s t h e hi g h e st l e v el of e d u c ati o n y o u h a v e c o m pl et e d ?  
  Di d n ot c o m pl et e hi g h s c h o ol  
  Hi g h s c h o ol c ertifi c at e  
  Tr a d e s c h o ol or n o n -u ni v ersit y p ost -s e c o n d ar y pr o gr a m  
  S o m e u ni v ersit y  
  B a c h el or’s d e gr e e  
  H i g h er t h a n a B a c h el or’ s d e gr e e 
  Ot h er, pl e as e s p e cif y _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
2 7. W h at i s y o ur c urr e nt m a rit al st at u s ?  
  Si n gl e  
  M arri e d or li vi n g wit h a p art n er  
  Di v or c e d or s e p ar at e d  
  Wi d o w e d  
 
2 8. H o w m a n y c hil dr e n d o y o u h a v e ? If n o n e, e nt er z er o.  
 
_ _ _ _ _  
  
2 9. H a s a n y b o d y i n y o ur f a mil y e v er h a d c a n c er ? ( Ot h er t h a n y o ur s elf ) 
  Y es  
  N o  
  
 1 7 9  
 
 
3 0. If y e s, pl e a s e m a r k a n ‘ x’ n e xt t o all t h at a p pl y.  
  P ar e nt  
  C hil dr e n  
  S p o us e  
  Si bli n g  
  Ot h ers  
 
3 1. H a s a n y b o d y i n y o ur f a mil y e v er h a d c ol o n c a n c er ? ( Ot h er t h a n y o ur s elf ) 
  Y es  
  N o  
 
3 2. If y e s, pl e a s e m a r k a n ‘ x’ n e xt t o all t h at a p pl y.  
  P ar e nt  
  C hil dr e n  
  S p o us e  
  Si bli n g  
  Ot h ers  
 
 
Pl e as e f e el fr e e t o pr o vi d e us wit h a n y ot h er c o m m e nt s or s u g g esti o ns a b o ut t u m or t esti n g 
f or i n h erit e d f or ms of c ol o n c a n c er.  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
 
  
 1 8 0  
 
W o ul d y o u li k e y o ur n a m e t o b e e nt er e d i nt o t h e pri z e dr a w f or a $ 5 0 0 gift 
c ar d ?  
 
  Y e s, pl e a s e  
  N o t h a n k s  
 
T h a n k y o u f or y o ur ti m e!  
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Appendix B  
Copy of the cover letter 
 
Hello!                                                                                                              
       You are invited to take part in a research study called Universal tumor screening for 
Lynch syndrome: Perspectives of patients regarding benefits and barriers. The study 
involves filling out one survey that is included with this letter.  
       You are being invited to take part in this study as a person who has had colon cancer. 
Researchers from Memorial University would like to study what patients think about 
screening colon cancer tumors for signs of a genetic condition called Lynch syndrome. This 
kind of screening is being done in other parts of Canada, but not yet in our province. We 
believe that patients’ opinions about colon cancer tumor screening would be helpful if a 
tumor screening program was ever started in Newfoundland and Labrador.  
 
        Filling out this survey is voluntary, and you are free to leave out any question you do 
not wish to answer. If you are not interested in taking part, please feel free to ignore the 
survey. If you do not wish to receive reminder mail-outs about the survey, please send us 
back the blank survey in the postage paid envelope provided and we will remove your name 
from the mailing list. You can also call us on the phone number 709-864-6605 to opt out of 
the survey.Taking part in this survey will not affect any healthcare you or your family 
receives. There are no names attached to the survey, so no one will know your answers. 
Your name will never be reported in any papers or reports prepared from the survey. The 
data we collect for this study will be stored for 5 years. Should you wish to withdraw from 
the study at any time, any survey data you have provided will be removed from the data set 
and destroyed.  
 
       Participants who wish can have their name entered in a prize draw for a $500 gift card. 
This will take place at the end of the study and the prize will be mailed to the winning 
participant. At the end of the survey, simply check “yes” and your name will be entered in 
the prize draw.  
     
        Filling out the survey should only take 15-20 minutes. Please send it back in the 
postage paid envelope provided. If you have any questions or concerns about the study or 
would like more information, please feel free to contact the lead researcher, Ms. Anusree 
Subramonian or her supervisor Dr. Holly Etchegary directly:  
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Dr. Holly Etchegary, Assistant Professor, Faculty of Medicine     
Patient Engagement Lead 
Phone: 709-864-6605; Email: holly.etchegary@med.mun.ca  
 
Anusree Subramonian,  
MSc Clinical Epidemiology (c), 
Faculty of Medicine 
Memorial University of Newfoundland 
Email: as7273@mun.ca 
 
Or you can talk to someone who is not involved with the study at all, but can advise you on 
your rights as a participant in a research study.  This person can be reached through: 
                  
Ethics Office at 709-777-6974 
Email at info@hrea.ca 
 
This study has been reviewed and given ethics approval by the Newfoundland and Labrador 
Health Research Ethics Board. 
 
 
 
We thank you for taking the time to give us your thoughts and opinions about colon cancer 
tumor screening.  
 
Sincerely,  
 
 
 
 
Holly Etchegary and Anusree Subramonian, on behalf of the research team 
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Appendix C  
Copy of the introduction letter 
Date  
 
Dear  
 A research study is being conducted by Memorial University, “Universal tumor screening for Lynch 
syndrome: Perspectives of patients regarding benefits and barriers.” This study will survey patients who 
have had colon cancer. Based on the study’s eligibility criteria, your name and contact information was 
selected from the Cancer Registry. The study involves filling out one survey that is included with this 
letter. Your study participation is completely voluntary and confidential.  
Lynch syndrome is a genetic form of colon cancer. People who have Lynch syndrome are at high risk for 
colon and several other kinds of cancers. Researchers believe it is important to identify these patients so 
that early screening of them and their family members can be started. There is a screening test for Lynch 
syndrome that can be done on a colon cancer tumor. If that test is abnormal, further testing can be 
done, including a blood test to check for genetic risk of Lynch syndrome.   
Researchers are interested in what people who have had colon cancer think about testing a colon cancer 
tumor for genetic forms of cancer. This kind of tumor testing is being done in other places in Canada. 
The researchers believe that patients’ opinions about testing a colon cancer tumor for genetic forms of 
cancer would be helpful if a tumor testing program was ever started in Newfoundland and Labrador.  
If you are interested in taking part, simply complete the survey and send it back to the researcher in the 
enclosed envelope.   If you do not wish to take part in the study or believe you have received this letter 
in error, please contact the lead study researcher directly. Her name is Holly Etchegary, and she can be 
reached at 709-864-6605 or by email at holly.etchegary@med.mun.ca. Holly is a researcher at the 
Faculty of Medicine, Memorial University. She is happy to remove your name from the list or to answer 
any questions you may have about the study.  
Thank you for taking the time to consider taking part in the study.  
 
Best regards,  
Susan Ryan, Manager Cancer and Cytology Registry  
 
 
 
 
 184 
 
 
